{"protocolSection":{"identificationModule":{"nctId":"NCT00802464","orgStudyIdInfo":{"id":"112077"},"secondaryIdInfos":[{"id":"2008-005120-86","type":"EUDRACT_NUMBER"},{"id":"2008","type":"NIH","link":"https://reporter.nih.gov/quickSearch/2008"}],"organization":{"fullName":"GlaxoSmithKline","class":"INDUSTRY"},"briefTitle":"Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine With Various Formulations in Adults >= 50 Years","officialTitle":"Immunogenicity and Safety Study of Different Formulations of GSK Biologicals' Herpes Zoster Vaccine 1437173A When Administered Twice in Adults Aged 50 Years and Older"},"statusModule":{"statusVerifiedDate":"2019-06","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2009-01-12","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2010-07-02","type":"ACTUAL"},"completionDateStruct":{"date":"2010-07-02","type":"ACTUAL"},"studyFirstSubmitDate":"2008-12-04","studyFirstSubmitQcDate":"2008-12-04","studyFirstPostDateStruct":{"date":"2008-12-05","type":"ESTIMATED"},"resultsFirstSubmitDate":"2017-08-10","resultsFirstSubmitQcDate":"2017-11-10","resultsFirstPostDateStruct":{"date":"2017-12-12","type":"ACTUAL"},"dispFirstSubmitDate":"2009-11-10","dispFirstSubmitQcDate":"2009-11-12","dispFirstPostDateStruct":{"date":"2009-11-16","type":"ESTIMATED"},"lastUpdateSubmitDate":"2019-06-11","lastUpdatePostDateStruct":{"date":"2019-06-26","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"GlaxoSmithKline","class":"INDUSTRY"}},"descriptionModule":{"briefSummary":"The goal of this randomized observer-blind trial is to further refine the formulation of vaccines containing GSK1437173A in older adults by comparing the cellular and humoral immune responses and the safety profiles of the different formulations."},"conditionsModule":{"conditions":["Herpes Zoster"],"keywords":["Cytokine","Vaccine","Herpes Zoster (HZ)","Cell mediated immunity (CMI)","Antibody response","Varicella Zoster Virus (VZV)","Shingles"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"PREVENTION","maskingInfo":{"masking":"TRIPLE","whoMasked":["PARTICIPANT","INVESTIGATOR","OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":410,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"GSK1437173A formulation 1 Group","type":"EXPERIMENTAL","description":"Male or female subjects, 50 years of age or above, who received 2 doses of GSK1437173A (gE/ASO1B and gE/ASO1E) formulation 1 vaccine, administered intramuscularly in the upper deltoid region of the non-dominant arm on a 0, 2 month schedule.","interventionNames":["Biological: Herpes zoster vaccine GSK1437173A"]},{"label":"GSK1437173A formulation 2 Group","type":"EXPERIMENTAL","description":"Male or female subjects, 50 years of age or above, who received 2 doses of GSK1437173A (gE/ASO1B and gE/ASO1E) GSK1437173A formulation 2 vaccine, administered intramuscularly in the upper deltoid region of the non-dominant arm on a 0, 2 month schedule.","interventionNames":["Biological: Herpes zoster vaccine GSK1437173A"]},{"label":"GSK1437173A formulation 3 Group","type":"EXPERIMENTAL","description":"Male or female subjects, 50 years of age or above, who received 2 doses of GSK1437173A (gE/ASO1B and gE/ASO1E) formulation 3 vaccine, administered intramuscularly in the upper deltoid region of the non-dominant arm on a 0, 2 month schedule.","interventionNames":["Biological: Herpes zoster vaccine GSK1437173A"]},{"label":"Control Group","type":"PLACEBO_COMPARATOR","description":"Male or female subjects, 50 years of age or above, who received 2 doses of saline solution (placebo), administered intramuscularly in the upper deltoid region of the non-dominant arm on a 0, 2 month schedule.","interventionNames":["Biological: Placebo"]}],"interventions":[{"type":"BIOLOGICAL","name":"Herpes zoster vaccine GSK1437173A","description":"2 vaccinations at Months 0 and 2 with GSK1437173A (different formulations)","armGroupLabels":["GSK1437173A formulation 1 Group","GSK1437173A formulation 2 Group","GSK1437173A formulation 3 Group"],"otherNames":["gE/AS01E","gE/AS01B"]},{"type":"BIOLOGICAL","name":"Placebo","description":"2 vaccinations at Months 0 and 2 with placebo","armGroupLabels":["Control Group"],"otherNames":["Placebo/Saline"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Frequency of gE-specific Cluster of Differentiation 4 (CD4+) T-cells Expressing at Least 2 Different Immunological Activation Markers","description":"The analysis focused on CD4+ T-cells expressing at least 2 immunological activation markers among Interferon gamma (IFN-γ), Interleukin 2 (IL-2), Tumour Necrosis Factor alpha (TNF-α) and CD40 Ligand (CD40L). Frequencies were determined by in vitro Intracellular Cytokine Staining (ICS).","timeFrame":"One month after the second vaccination (Month 3)"},{"measure":"Frequency of Varicella-Zoster Virus (VZV)-Specific CD4+ T-cells Expressing at Least 2 Different Immunological Activation Markers","description":"The analysis focused on CD4+ T-cells expressing at least 2 immunological activation markers among Interferon gamma (IFN-γ), Interleukin 2 (IL-2), Tumour Necrosis Factor alpha (TNF-α) and CD40 Ligand (CD40L). Frequencies were determined by in vitro Intracellular Cytokine Staining (ICS).","timeFrame":"One month after the second vaccination (Month 3)"},{"measure":"Anti-glycoprotein E (gE) Antibody Concentrations","description":"Concentrations were determined by enzyme-linked immunosorbent assay (ELISA) and are presented as geometric mean concentrations (GMCs), expressed in milli-international units per milliliter (mIU/mL).","timeFrame":"One month after the second vaccination (Month 3)"},{"measure":"Anti-VZV Antibody Concentrations","description":"Concentrations were determined by enzyme-linked immunosorbent assay (ELISA) and are presented as geometric mean concentrations (GMCs), expressed in milli-international units per milliliter (mIU/mL).","timeFrame":"One month after the second vaccination (Month 3)"}],"secondaryOutcomes":[{"measure":"Frequencies of gE-specific CD4+ T-cells Expressing at Least 2 Different Immunological Activation Markers","description":"The analysis focused on CD4+ T-cells expressing at least 2 immunological activation markers among Interferon gamma (IFN-γ), Interleukin 2 (IL-2), Tumour Necrosis Factor alpha (TNF-α) and CD40 Ligand (CD40L). Frequencies were determined by in vitro Intracellular Cytokine Staining (ICS).","timeFrame":"At Month 0 and at Month 2"},{"measure":"Frequency of VZV-specific CD4+ T-cells Expressing at Least 2 Different Immunological Activation Markers","description":"The analysis focused on CD4+ T-cells expressing at least 2 immunological activation markers among Interferon gamma (IFN-γ), Interleukin 2 (IL-2), Tumour Necrosis Factor alpha (TNF-α) and CD40 Ligand (CD40L). Frequencies were determined by in vitro Intracellular Cytokine Staining (ICS).","timeFrame":"At Month 0 and at Month 2"},{"measure":"Anti-gE Antibody Concentrations","description":"Concentrations were determined by enzyme-linked immunosorbent assay (ELISA) and are presented as geometric mean concentrations (GMCs), expressed in milli-international units per milliliter (mIU/mL).","timeFrame":"At Month 0 and at Month 2"},{"measure":"Anti-VZV Antibody Concentrations","description":"Concentrations were determined by enzyme-linked immunosorbent assay (ELISA) and are presented as geometric mean concentrations (GMCs), expressed in milli-international units per milliliter (mIU/mL).","timeFrame":"At Month 0 and at Month 2"},{"measure":"Number of Subjects With Any and Grade 3 Solicited Local Symptoms","description":"Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = pain that prevented normal activity. Grade 3 redness/swelling = redness/swelling spreading beyond 100 millimeters (mm) of injection site.","timeFrame":"During the 7-day (Days 0-6) post-vaccination period after each dose and across doses"},{"measure":"Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms.","description":"Assessed solicited general symptoms were fatigue, gastrointestinal symptoms, headache, myalgia and fever \\[defined as axillary temperature equal to or above (≥) 37.5 degrees Celsius (°C)\\]. Any = occurrence of the symptom regardless of intensity grade. Grade 3 symptom = symptom that prevented normal activity. Grade 3 fever = fever higher than (\\>) 39.0 °C. Related = symptom assessed by the investigator as related to the vaccination.","timeFrame":"During the 7-day (Days 0-6)post-vaccination period after each dose and across doses"},{"measure":"Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs)","description":"An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 AE = an AE which prevented normal, everyday activities. Related = AE assessed by the investigator as related to the vaccination.","timeFrame":"Within the 30-day (Days 0-29) post-vaccination period"},{"measure":"Number of Subjects With Serious Adverse Events (SAEs)","description":"Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.","timeFrame":"From Month 0 up to Month 8"},{"measure":"Number of Subjects With Serious Adverse Events (SAEs)","description":"Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.","timeFrame":"During the period after Month 8 up to the end of the study at Month 14"},{"measure":"Number of Subjects With Any New Onset of Autoimmune Diseases (NOADs)","description":"Any new onset of autoimmune diseases were to be reported throughout the entire study period, whether or not they were considered to be possibly related to the treatment administration. These included neurological/demyelinating events, rheumatic and connective diseases, autoimmune endocrine diseases, inflammatory bowel diseases, autoimmune blood disorders, inflammatory skin disorders, other autoimmune/inflammatory events, autoimmune bullous skin diseases, vasculitis and liver autoimmune diseases.","timeFrame":"From Month 0 until Month 8"},{"measure":"Number of Subjects With Any New Onset of Autoimmune Diseases (NOADs)","description":"Any new onset of autoimmune diseases were to be reported throughout the entire study period, whether or not they were considered to be possibly related to the treatment administration. These included neurological/demyelinating events, rheumatic and connective diseases, autoimmune endocrine diseases, inflammatory bowel diseases, autoimmune blood disorders, inflammatory skin disorders, other autoimmune/inflammatory events, autoimmune bullous skin diseases, vasculitis and liver autoimmune diseases.","timeFrame":"During the period after Month 8 up to the end of the study at Month 14"},{"measure":"Number of Subjects With Suspected Cases of Herpes Zoster (HZ)","description":"A suspected case of HZ was defined as a rash consistent with HZ.","timeFrame":"From Month 0 until Month 8"},{"measure":"Number of Subjects With Suspected Cases of Herpes Zoster (HZ)","description":"A suspected case of HZ is defined as a rash consistent with HZ.","timeFrame":"During the period after Month 8 up to the end of the study at Month 14"},{"measure":"Number of Subjects With Haematological and Biochemical Parameters Unknown, Below, Within or Above the Normal Ranges","description":"Hematological and biochemical parameters assessed were Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Basophils (BAS), Calcium (CAL), Creatinine (CREA), Eosinophils (EOS), Fibrinogen (FIBR), Hematocrit (HCT), Hemoglobin (HGB), Lactate Dehydrogenase (LDH), Lymphocytes (LYM), Mean Corpuscular Volume (MCV), Monocytes (MON), Neutrophils (NEU), Partial Thromboplastin Time (PTT), Platelets (PLAT), Prothrombin Time (PT), Red Blood Cells (RBC), Total Protein (TP) and White Blood Cells (WBC).","timeFrame":"At Month 0"},{"measure":"Number of Subjects With Haematological and Biochemical Parameters Unknown, Below, Within or Above the Normal Ranges","description":"Hematological and biochemical parameters assessed were Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Basophils (BAS), Calcium (CAL), Creatinine (CREA), Eosinophils (EOS), Fibrinogen (FIBR), Hematocrit (HCT), Hemoglobin (HGB), Lactate Dehydrogenase (LDH), Lymphocytes (LYM), Mean Corpuscular Volume (MCV), Monocytes (MON), Neutrophils (NEU), Partial Thromboplastin Time (PTT), Platelets (PLAT), Prothrombin Time (PT), Red Blood Cells (RBC), Total Protein (TP) and White Blood Cells (WBC).","timeFrame":"At Month 2"},{"measure":"Number of Subjects With Haematological and Biochemical Parameters Unknown, Below, Within or Above the Normal Ranges","description":"Hematological and biochemical parameters assessed were Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Basophils (BAS), Calcium (CAL), Creatinine (CREA), Eosinophils (EOS), Fibrinogen (FIBR), Hematocrit (HCT), Hemoglobin (HGB), Lactate Dehydrogenase (LDH), Lymphocytes (LYM), Mean Corpuscular Volume (MCV), Monocytes (MON), Neutrophils (NEU), Partial Thromboplastin Time (PTT), Platelets (PLAT), Prothrombin Time (PT), Red Blood Cells (RBC), Total Protein (TP) and White Blood Cells (WBC).","timeFrame":"At Month 3"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* A male or female 50 years of age or above at the time of the first vaccination;\n* Written informed consent obtained from the subject;\n* Subjects who the investigator believes that they can and will comply with the requirements of the protocol should be enrolled in the study;\n* If the subject is female, she must be of non-childbearing potential, or if she is of childbearing potential, she must practice adequate contraception for 30 days prior to vaccination, have a negative pregnancy test and continue such precautions for 2 months after completion of the vaccination series.\n\nExclusion Criteria:\n\n* Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine(s) within 30 days preceding the first dose of study vaccine, or planned use during the study period;\n* Chronic administration (defined as more than 14 consecutive days) of immunosuppressants or other immune-modifying drugs within three months prior to the first vaccine dose.\n* Planned administration/ administration of a vaccine not foreseen by the study protocol within one month before the first study vaccination or scheduled within 30 days after study vaccination;\n* Previous vaccination against HZ;\n* Previous vaccination against varicella;\n* History of HZ;\n* History of allergic disease or reactions likely to be exacerbated by any component of the vaccine;\n* Any confirmed or suspected immunosuppressive or immunodeficient condition resulting from disease or immunosuppressive/cytotoxic therapy;\n* Administration of immunoglobulins and/or any blood products within the 3 months preceding the first injection of study vaccine or planned administration during the study period;\n* Acute disease at the time of enrolment.\n* Any other condition that, in the opinion of the investigator, might interfere with the evaluations required by the study;\n* History of or current drug and/or alcohol abuse;\n* Pregnant or lactating female;\n* Female planning to become pregnant or planning to discontinue contraceptive precautions if of childbearing potential.","healthyVolunteers":true,"sex":"ALL","minimumAge":"50 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"GSK Clinical Trials","affiliation":"GlaxoSmithKline","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"GSK Investigational Site","city":"Phoenix","state":"Arizona","zip":"85020","country":"United States","geoPoint":{"lat":33.44838,"lon":-112.07404}},{"facility":"GSK Investigational Site","city":"Pembroke Pines","state":"Florida","zip":"33024","country":"United States","geoPoint":{"lat":26.00315,"lon":-80.22394}},{"facility":"GSK Investigational Site","city":"Las Vegas","state":"Nevada","zip":"89130","country":"United States","geoPoint":{"lat":36.17497,"lon":-115.13722}},{"facility":"GSK Investigational Site","city":"Edison","state":"New Jersey","zip":"08817","country":"United States","geoPoint":{"lat":40.51872,"lon":-74.4121}},{"facility":"GSK Investigational Site","city":"Raleigh","state":"North Carolina","zip":"27612","country":"United States","geoPoint":{"lat":35.7721,"lon":-78.63861}},{"facility":"GSK Investigational Site","city":"Cleveland","state":"Ohio","zip":"44122","country":"United States","geoPoint":{"lat":41.4995,"lon":-81.69541}},{"facility":"GSK Investigational Site","city":"Pittsburgh","state":"Pennsylvania","zip":"15236","country":"United States","geoPoint":{"lat":40.44062,"lon":-79.99589}},{"facility":"GSK Investigational Site","city":"Hradec Králové","zip":"500 01","country":"Czechia","geoPoint":{"lat":50.20923,"lon":15.83277}},{"facility":"GSK Investigational Site","city":"Barcelona","zip":"08035","country":"Spain","geoPoint":{"lat":41.38879,"lon":2.15899}},{"facility":"GSK Investigational Site","city":"Barcelona","country":"Spain","geoPoint":{"lat":41.38879,"lon":2.15899}},{"facility":"GSK Investigational Site","city":"Mahadahonda( Madrid","zip":"28222","country":"Spain"},{"facility":"GSK Investigational Site","city":"Marid","zip":"28040","country":"Spain"}]},"referencesModule":{"references":[{"pmid":"23904292","type":"BACKGROUND","citation":"Chlibek R, Bayas JM, Collins H, de la Pinta ML, Ledent E, Mols JF, Heineman TC. Safety and immunogenicity of an AS01-adjuvanted varicella-zoster virus subunit candidate vaccine against herpes zoster in adults >=50 years of age. J Infect Dis. 2013 Dec 15;208(12):1953-61. doi: 10.1093/infdis/jit365. Epub 2013 Jul 31."}],"seeAlsoLinks":[{"label":"Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.","url":"https://www.clinicalstudydatarequest.com"}],"availIpds":[{"id":"112077","type":"Statistical Analysis Plan","url":"https://www.clinicalstudydatarequest.com","comment":"For additional information about this study please refer to the GSK Clinical Study Register"},{"id":"112077","type":"Clinical Study Report","url":"https://www.clinicalstudydatarequest.com","comment":"For additional information about this study please refer to the GSK Clinical Study Register"},{"id":"112077","type":"Informed Consent Form","url":"https://www.clinicalstudydatarequest.com","comment":"For additional information about this study please refer to the GSK Clinical Study Register"},{"id":"112077","type":"Study Protocol","url":"https://www.clinicalstudydatarequest.com","comment":"For additional information about this study please refer to the GSK Clinical Study Register"},{"id":"112077","type":"Dataset Specification","url":"https://www.clinicalstudydatarequest.com","comment":"For additional information about this study please refer to the GSK Clinical Study Register"},{"id":"112077","type":"Annotated Case Report Form","url":"https://www.clinicalstudydatarequest.com","comment":"For additional information about this study please refer to the GSK Clinical Study Register"},{"id":"112077","type":"Individual Participant Data Set","url":"https://www.clinicalstudydatarequest.com","comment":"For additional information about this study please refer to the GSK Clinical Study Register"}]},"ipdSharingStatementModule":{"ipdSharing":"YES","description":"IPD for this study will be made available via the Clinical Study Data Request site.","infoTypes":["STUDY_PROTOCOL","SAP","ICF","CSR"],"timeFrame":"IPD is available via the Clinical Study Data Request site (click on the link provided below)","accessCriteria":"Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.","url":"http://clinicalstudydatarequest.com"}},"resultsSection":{"participantFlowModule":{"groups":[{"id":"FG000","title":"Placebo Group","description":"Male or female subjects, 50 years of age or above, who received 2 doses of saline solution (placebo), administered intramuscularly in the upper deltoid region of the non-dominant arm, on a 0, 2 month schedule."},{"id":"FG001","title":"GSK1437173A Formulation 3 Group","description":"Male or female subjects, 50 years of age or above, who received 2 doses of GSK1437173A (gE/AS01B and gE/AS01E) formulation 3 vaccine, administered intramuscularly in the upper deltoid region of the non-dominant arm, on a 0, 2 month schedule."},{"id":"FG002","title":"GSK1437173A Formulation 2 Group","description":"Male or female subjects, 50 years of age or above, who received 2 doses of GSK1437173A (gE/AS01B and gE/AS01E) formulation 2 vaccine, administered intramuscularly in the upper deltoid region of the non-dominant arm, on a 0, 2 month schedule."},{"id":"FG003","title":"GSK1437173A Formulation 1 Group","description":"Male or female subjects, 50 years of age or above, who received 2 doses of GSK1437173A (gE/AS01B and gE/AS01E) formulation 1 vaccine, administered intramuscularly in the upper deltoid region of the non-dominant arm, on a 0, 2 month schedule."}],"periods":[{"title":"Month 0 - Month 8","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"38"},{"groupId":"FG001","numSubjects":"73"},{"groupId":"FG002","numSubjects":"149"},{"groupId":"FG003","numSubjects":"150"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"38"},{"groupId":"FG001","numSubjects":"70"},{"groupId":"FG002","numSubjects":"142"},{"groupId":"FG003","numSubjects":"141"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"3"},{"groupId":"FG002","numSubjects":"7"},{"groupId":"FG003","numSubjects":"9"}]}],"dropWithdraws":[{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"2"}]},{"type":"Protocol Violation","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"0"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"2"},{"groupId":"FG003","numSubjects":"5"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"2"},{"groupId":"FG003","numSubjects":"2"}]},{"type":"Other","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"0"}]}]},{"title":"Month 8 - Month 14","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"34"},{"groupId":"FG001","numSubjects":"65"},{"groupId":"FG002","numSubjects":"130"},{"groupId":"FG003","numSubjects":"126"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"33"},{"groupId":"FG001","numSubjects":"63"},{"groupId":"FG002","numSubjects":"129"},{"groupId":"FG003","numSubjects":"126"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"2"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"0"}]}],"dropWithdraws":[{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"0"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"Placebo Group","description":"Male or female subjects, 50 years of age or above, who received 2 doses of saline solution (placebo), administered intramuscularly in the upper deltoid region of the non-dominant arm, on a 0, 2 month schedule."},{"id":"BG001","title":"GSK1437173A Formulation 3 Group","description":"Male or female subjects, 50 years of age or above, who received 2 doses of GSK1437173A (gE/AS01B and gE/AS01E) formulation 3 vaccine, administered intramuscularly in the upper deltoid region of the non-dominant arm, on a 0, 2 month schedule."},{"id":"BG002","title":"GSK1437173A Formulation 2 Group","description":"Male or female subjects, 50 years of age or above, who received 2 doses of GSK1437173A (gE/AS01B and gE/AS01E) formulation 2 vaccine, administered intramuscularly in the upper deltoid region of the non-dominant arm, on a 0, 2 month schedule."},{"id":"BG003","title":"GSK1437173A Formulation 1 Group","description":"Male or female subjects, 50 years of age or above, who received 2 doses of GSK1437173A (gE/AS01B and gE/AS01E) formulation 1 vaccine, administered intramuscularly in the upper deltoid region of the non-dominant arm, on a 0, 2 month schedule."},{"id":"BG004","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"38"},{"groupId":"BG001","value":"73"},{"groupId":"BG002","value":"149"},{"groupId":"BG003","value":"150"},{"groupId":"BG004","value":"410"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"Years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"65.0","spread":"9.0"},{"groupId":"BG001","value":"65.1","spread":"8.7"},{"groupId":"BG002","value":"65.1","spread":"9.9"},{"groupId":"BG003","value":"65.0","spread":"8.9"},{"groupId":"BG004","value":"65.0","spread":"9.2"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"22"},{"groupId":"BG001","value":"40"},{"groupId":"BG002","value":"89"},{"groupId":"BG003","value":"81"},{"groupId":"BG004","value":"232"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"16"},{"groupId":"BG001","value":"33"},{"groupId":"BG002","value":"60"},{"groupId":"BG003","value":"69"},{"groupId":"BG004","value":"178"}]}]}]},{"title":"Race/Ethnicity, Customized","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"title":"Race/Ethnicity","categories":[{"title":"African Heritage / African American","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"2"},{"groupId":"BG003","value":"6"},{"groupId":"BG004","value":"9"}]},{"title":"American Indian or Alaskan Native","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"2"},{"groupId":"BG004","value":"3"}]},{"title":"Other","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"1"},{"groupId":"BG004","value":"1"}]},{"title":"White - Arabic / North African Heritage","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"1"}]},{"title":"White - Caucasian / European Heritage","measurements":[{"groupId":"BG000","value":"38"},{"groupId":"BG001","value":"72"},{"groupId":"BG002","value":"145"},{"groupId":"BG003","value":"141"},{"groupId":"BG004","value":"396"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Frequency of gE-specific Cluster of Differentiation 4 (CD4+) T-cells Expressing at Least 2 Different Immunological Activation Markers","description":"The analysis focused on CD4+ T-cells expressing at least 2 immunological activation markers among Interferon gamma (IFN-γ), Interleukin 2 (IL-2), Tumour Necrosis Factor alpha (TNF-α) and CD40 Ligand (CD40L). Frequencies were determined by in vitro Intracellular Cytokine Staining (ICS).","populationDescription":"The analyses were performed on the According-to-Protocol (ATP) Cohort for immunogenicity, which included all evaluable subjects from Month 0 to 3. This included those subjects who met all eligibility criteria, complied with the protocol, with no elimination criteria during this part of the study and for whom immunogenicity measures were available.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"gE-specific CD4+ T-cells/million T-cells","timeFrame":"One month after the second vaccination (Month 3)","groups":[{"id":"OG000","title":"Placebo Group","description":"Male or female subjects, 50 years of age or above, who received 2 doses of saline solution (placebo), administered intramuscularly in the upper deltoid region of the non-dominant arm, on a 0, 2 month schedule."},{"id":"OG001","title":"GSK1437173A Formulation 3 Group","description":"Male or female subjects, 50 years of age or above, who received 2 doses of GSK1437173A (gE/AS01B and gE/AS01E) formulation 3 vaccine, administered intramuscularly in the upper deltoid region of the non-dominant arm, on a 0, 2 month schedule."},{"id":"OG002","title":"GSK1437173A Formulation 2 Group","description":"Male or female subjects, 50 years of age or above, who received 2 doses of GSK1437173A (gE/AS01B and gE/AS01E) formulation 2 vaccine, administered intramuscularly in the upper deltoid region of the non-dominant arm, on a 0, 2 month schedule."},{"id":"OG003","title":"GSK1437173A Formulation 1 Group","description":"Male or female subjects, 50 years of age or above, who received 2 doses of GSK1437173A (gE/AS01B and gE/AS01E) formulation 1 vaccine, administered intramuscularly in the upper deltoid region of the non-dominant arm, on a 0, 2 month schedule."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"32"},{"groupId":"OG001","value":"70"},{"groupId":"OG002","value":"126"},{"groupId":"OG003","value":"125"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"231.82","spread":"411.84"},{"groupId":"OG001","value":"570.36","spread":"610.10"},{"groupId":"OG002","value":"2172.37","spread":"1805.51"},{"groupId":"OG003","value":"2582.80","spread":"2154.92"}]}]}],"analyses":[{"groupIds":["OG001","OG003"],"groupDescription":"Fold increase in frequency of gE-specific CD4+ T-cells secreting at least 2 different immunological activation markers among IFN-γ, IL-2, TNF-α and CD40L for GSK1437173A Formulation 1 over GSK1437173A Formulation 3 Group.","nonInferiorityType":"OTHER","paramType":"Fold increase","paramValue":"5.21","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"3.89","ciUpperLimit":"6.98"},{"groupIds":["OG001","OG002"],"groupDescription":"Fold increase in frequency of gE-specific CD4+ T-cells secreting at least 2 different immunological activation markers among IFN-γ, IL-2, TNF-α and CD40L for GSK1437173A Formulation 2 over GSK1437173A Formulation 3 Group.","nonInferiorityType":"OTHER","paramType":"Fold increase","paramValue":"4.02","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"3","ciUpperLimit":"5.4"},{"groupIds":["OG002","OG003"],"groupDescription":"Fold increase in frequency of gE-specific CD4+ T-cells secreting at least 2 different immunological activation markers among IFN-γ, IL-2, TNF-α and CD40L for GSK1437173A Formulation 1 over GSK1437173A Formulation 2 Group.","nonInferiorityType":"OTHER","paramType":"Fold increase","paramValue":"1.3","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"1.07","ciUpperLimit":"1.58"}]},{"type":"PRIMARY","title":"Frequency of Varicella-Zoster Virus (VZV)-Specific CD4+ T-cells Expressing at Least 2 Different Immunological Activation Markers","description":"The analysis focused on CD4+ T-cells expressing at least 2 immunological activation markers among Interferon gamma (IFN-γ), Interleukin 2 (IL-2), Tumour Necrosis Factor alpha (TNF-α) and CD40 Ligand (CD40L). Frequencies were determined by in vitro Intracellular Cytokine Staining (ICS).","populationDescription":"The analyses were performed on the According-to-Protocol (ATP) Cohort for immunogenicity, which included all evaluable subjects from Month 0 to 3. This included those subjects who met all eligibility criteria, complied with the protocol, with no elimination criteria during this part of the study and for whom immunogenicity measures were available.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"VZV-specific CD4+ T-cells/million T-cell","timeFrame":"One month after the second vaccination (Month 3)","groups":[{"id":"OG000","title":"Placebo Group","description":"Male or female subjects, 50 years of age or above, who received 2 doses of saline solution (placebo), administered intramuscularly in the upper deltoid region of the non-dominant arm, on a 0, 2 month schedule."},{"id":"OG001","title":"GSK1437173A Formulation 3 Group","description":"Male or female subjects, 50 years of age or above, who received 2 doses of GSK1437173A (gE/AS01B and gE/AS01E) formulation 3 vaccine, administered intramuscularly in the upper deltoid region of the non-dominant arm, on a 0, 2 month schedule."},{"id":"OG002","title":"GSK1437173A Formulation 2 Group","description":"Male or female subjects, 50 years of age or above, who received 2 doses of GSK1437173A (gE/AS01B and gE/AS01E) formulation 2 vaccine, administered intramuscularly in the upper deltoid region of the non-dominant arm, on a 0, 2 month schedule."},{"id":"OG003","title":"GSK1437173A Formulation 1 Group","description":"Male or female subjects, 50 years of age or above, who received 2 doses of GSK1437173A (gE/AS01B and gE/AS01E) formulation 1 vaccine, administered intramuscularly in the upper deltoid region of the non-dominant arm, on a 0, 2 month schedule."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"32"},{"groupId":"OG001","value":"70"},{"groupId":"OG002","value":"126"},{"groupId":"OG003","value":"125"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"457.43","spread":"275.25"},{"groupId":"OG001","value":"523.12","spread":"396.01"},{"groupId":"OG002","value":"1093.08","spread":"927.18"},{"groupId":"OG003","value":"1270.79","spread":"1106.45"}]}]}],"analyses":[{"groupIds":["OG001","OG003"],"groupDescription":"Fold increase in frequency of gE-specific CD4+ T-cells secreting at least 2 different immunological activation markers among IFN-γ, IL-2, TNF-α and CD40L for GSK1437173A Formulation 1 over GSK1437173A Formulation 3 Group.","nonInferiorityType":"OTHER","paramType":"Fold increase","paramValue":"2.12","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"1.67","ciUpperLimit":"2.69"},{"groupIds":["OG001","OG002"],"groupDescription":"Fold increase in frequency of gE-specific CD4+ T-cells secreting at least 2 different immunological activation markers among IFN-γ, IL-2, TNF-α and CD40L for GSK1437173A Formulation 2 over GSK1437173A Formulation 3 Group.","nonInferiorityType":"OTHER","paramType":"Fold increase","paramValue":"1.63","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"1.28","ciUpperLimit":"2.07"},{"groupIds":["OG002","OG003"],"groupDescription":"Fold increase in frequency of gE-specific CD4+ T-cells secreting at least 2 different immunological activation markers among IFN-γ, IL-2, TNF-α and CD40L for GSK1437173A Formulation 1 over GSK1437173A Formulation 2 Group.","nonInferiorityType":"OTHER","paramType":"Fold increase","paramValue":"1.3","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"1.09","ciUpperLimit":"1.56"}]},{"type":"PRIMARY","title":"Anti-glycoprotein E (gE) Antibody Concentrations","description":"Concentrations were determined by enzyme-linked immunosorbent assay (ELISA) and are presented as geometric mean concentrations (GMCs), expressed in milli-international units per milliliter (mIU/mL).","populationDescription":"The analyses were performed on the According-to-Protocol (ATP) Cohort for immunogenicity, which included all evaluable subjects from Month 0 to 3. This included those subjects who met all eligibility criteria, complied with the protocol, with no elimination criteria during this part of the study and for whom immunogenicity measures were available.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"mIU/mL","timeFrame":"One month after the second vaccination (Month 3)","groups":[{"id":"OG000","title":"Placebo Group","description":"Male or female subjects, 50 years of age or above, who received 2 doses of saline solution (placebo), administered intramuscularly in the upper deltoid region of the non-dominant arm, on a 0, 2 month schedule."},{"id":"OG001","title":"GSK1437173A Formulation 3 Group","description":"Male or female subjects, 50 years of age or above, who received 2 doses of GSK1437173A (gE/AS01B and gE/AS01E) formulation 3 vaccine, administered intramuscularly in the upper deltoid region of the non-dominant arm, on a 0, 2 month schedule."},{"id":"OG002","title":"GSK1437173A Formulation 2 Group","description":"Male or female subjects, 50 years of age or above, who received 2 doses of GSK1437173A (gE/AS01B and gE/AS01E) formulation 2 vaccine, administered intramuscularly in the upper deltoid region of the non-dominant arm, on a 0, 2 month schedule."},{"id":"OG003","title":"GSK1437173A Formulation 1 Group","description":"Male or female subjects, 50 years of age or above, who received 2 doses of GSK1437173A (gE/AS01B and gE/AS01E) formulation 1 vaccine, administered intramuscularly in the upper deltoid region of the non-dominant arm, on a 0, 2 month schedule."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"36"},{"groupId":"OG001","value":"70"},{"groupId":"OG002","value":"133"},{"groupId":"OG003","value":"132"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1987.0","lowerLimit":"1405.8","upperLimit":"2808.6"},{"groupId":"OG001","value":"14627.6","lowerLimit":"11347.9","upperLimit":"18855.1"},{"groupId":"OG002","value":"49531.5","lowerLimit":"44269.3","upperLimit":"55419.2"},{"groupId":"OG003","value":"68798.2","lowerLimit":"61596.8","upperLimit":"76841.5"}]}]}],"analyses":[{"groupIds":["OG001","OG003"],"groupDescription":"Fold increase in anti-gE antibody concentrations for GSK1437173A Formulation 1 Group over GSK1437173A Formulation 3 Group.","nonInferiorityType":"OTHER","paramType":"Fold increase","paramValue":"4.72","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"3.81","ciUpperLimit":"5.85"},{"groupIds":["OG001","OG002"],"groupDescription":"Fold increase in anti-gE antibody concentrations for GSK1437173A Formulation 2 Group over GSK1437173A Formulation 3 Group.","nonInferiorityType":"OTHER","paramType":"Fold increase","paramValue":"3.36","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"2.72","ciUpperLimit":"4.17"},{"groupIds":["OG002","OG003"],"groupDescription":"Fold increase in anti-gE antibody concentrations for GSK1437173A Formulation 1 Group over GSK1437173A Formulation 2 Group.","nonInferiorityType":"OTHER","paramType":"Fold increase","paramValue":"1.4","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"1.17","ciUpperLimit":"1.68"}]},{"type":"PRIMARY","title":"Anti-VZV Antibody Concentrations","description":"Concentrations were determined by enzyme-linked immunosorbent assay (ELISA) and are presented as geometric mean concentrations (GMCs), expressed in milli-international units per milliliter (mIU/mL).","populationDescription":"The analyses were performed on the According-to-Protocol (ATP) Cohort for immunogenicity, which included all evaluable subjects from Month 0 to 3. This included those subjects who met all eligibility criteria, complied with the protocol, with no elimination criteria during this part of the study and for whom immunogenicity measures were available.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"mIU/mL","timeFrame":"One month after the second vaccination (Month 3)","groups":[{"id":"OG000","title":"Placebo Group","description":"Male or female subjects, 50 years of age or above, who received 2 doses of saline solution (placebo), administered intramuscularly in the upper deltoid region of the non-dominant arm, on a 0, 2 month schedule."},{"id":"OG001","title":"GSK1437173A Formulation 3 Group","description":"Male or female subjects, 50 years of age or above, who received 2 doses of GSK1437173A (gE/AS01B and gE/AS01E) formulation 3 vaccine, administered intramuscularly in the upper deltoid region of the non-dominant arm, on a 0, 2 month schedule."},{"id":"OG002","title":"GSK1437173A Formulation 2 Group","description":"Male or female subjects, 50 years of age or above, who received 2 doses of GSK1437173A (gE/AS01B and gE/AS01E) formulation 2 vaccine, administered intramuscularly in the upper deltoid region of the non-dominant arm, on a 0, 2 month schedule."},{"id":"OG003","title":"GSK1437173A Formulation 1 Group","description":"Male or female subjects, 50 years of age or above, who received 2 doses of GSK1437173A (gE/AS01B and gE/AS01E) formulation 1 vaccine, administered intramuscularly in the upper deltoid region of the non-dominant arm, on a 0, 2 month schedule."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"36"},{"groupId":"OG001","value":"70"},{"groupId":"OG002","value":"133"},{"groupId":"OG003","value":"132"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1423.2","lowerLimit":"1097.8","upperLimit":"1845.0"},{"groupId":"OG001","value":"2786.4","lowerLimit":"2445.1","upperLimit":"3175.3"},{"groupId":"OG002","value":"4565.4","lowerLimit":"4357.0","upperLimit":"4783.7"},{"groupId":"OG003","value":"4972.8","lowerLimit":"4802.7","upperLimit":"5148.8"}]}]}],"analyses":[{"groupIds":["OG001","OG003"],"groupDescription":"Fold increase in anti-gE antibody concentrations for GSK1437173A Formulation 1 Group over GSK1437173A Formulation 3 Group.","nonInferiorityType":"OTHER","paramType":"Fold increase","paramValue":"3.21","ciPctValue":"36","ciNumSides":"TWO_SIDED","ciLowerLimit":"2.64","ciUpperLimit":"3.9"},{"groupIds":["OG001","OG002"],"groupDescription":"Fold increase in anti-gE antibody concentrations for GSK1437173A Formulation 2 Group over GSK1437173A Formulation 3 Group.","nonInferiorityType":"OTHER","paramType":"Fold increase","paramValue":"2.44","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"2.02","ciUpperLimit":"2.97"},{"groupIds":["OG002","OG003"],"groupDescription":"Fold increase in anti-gE antibody concentrations for GSK1437173A Formulation 1 Group over GSK1437173A Formulation 2 Group.","nonInferiorityType":"OTHER","paramType":"Fold increase","paramValue":"1.31","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"1.12","ciUpperLimit":"1.54"}]},{"type":"SECONDARY","title":"Frequencies of gE-specific CD4+ T-cells Expressing at Least 2 Different Immunological Activation Markers","description":"The analysis focused on CD4+ T-cells expressing at least 2 immunological activation markers among Interferon gamma (IFN-γ), Interleukin 2 (IL-2), Tumour Necrosis Factor alpha (TNF-α) and CD40 Ligand (CD40L). Frequencies were determined by in vitro Intracellular Cytokine Staining (ICS).","populationDescription":"The analyses were performed on the According-to-Protocol (ATP) Cohort for immunogenicity, which included all evaluable subjects from Month 0 to 3. This included those subjects who met all eligibility criteria, complied with the protocol, with no elimination criteria during this part of the study and for whom immunogenicity measures were available.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"gE-specific CD4+ T-cells/million T-cells","timeFrame":"At Month 0 and at Month 2","groups":[{"id":"OG000","title":"Placebo Group","description":"Male or female subjects, 50 years of age or above, who received 2 doses of saline solution (placebo), administered intramuscularly in the upper deltoid region of the non-dominant arm, on a 0, 2 month schedule."},{"id":"OG001","title":"GSK1437173A Formulation 3 Group","description":"Male or female subjects, 50 years of age or above, who received 2 doses of GSK1437173A (gE/AS01B and gE/AS01E) formulation 3 vaccine, administered intramuscularly in the upper deltoid region of the non-dominant arm, on a 0, 2 month schedule."},{"id":"OG002","title":"GSK1437173A Formulation 2 Group","description":"Male or female subjects, 50 years of age or above, who received 2 doses of GSK1437173A (gE/AS01B and gE/AS01E) formulation 2 vaccine, administered intramuscularly in the upper deltoid region of the non-dominant arm, on a 0, 2 month schedule."},{"id":"OG003","title":"GSK1437173A Formulation 1 Group","description":"Male or female subjects, 50 years of age or above, who received 2 doses of GSK1437173A (gE/AS01B and gE/AS01E) formulation 1 vaccine, administered intramuscularly in the upper deltoid region of the non-dominant arm, on a 0, 2 month schedule."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"35"},{"groupId":"OG001","value":"70"},{"groupId":"OG002","value":"132"},{"groupId":"OG003","value":"133"}]}],"classes":[{"title":"Month 0","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"35"},{"groupId":"OG001","value":"65"},{"groupId":"OG002","value":"132"},{"groupId":"OG003","value":"133"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"210.18","spread":"363.37"},{"groupId":"OG001","value":"130.98","spread":"115.90"},{"groupId":"OG002","value":"196.52","spread":"217.94"},{"groupId":"OG003","value":"173.48","spread":"203.54"}]}]},{"title":"Month 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"33"},{"groupId":"OG001","value":"70"},{"groupId":"OG002","value":"126"},{"groupId":"OG003","value":"127"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"185.59","spread":"310.06"},{"groupId":"OG001","value":"189.46","spread":"188.80"},{"groupId":"OG002","value":"463.79","spread":"386.94"},{"groupId":"OG003","value":"430.50","spread":"323.88"}]}]}]},{"type":"SECONDARY","title":"Frequency of VZV-specific CD4+ T-cells Expressing at Least 2 Different Immunological Activation Markers","description":"The analysis focused on CD4+ T-cells expressing at least 2 immunological activation markers among Interferon gamma (IFN-γ), Interleukin 2 (IL-2), Tumour Necrosis Factor alpha (TNF-α) and CD40 Ligand (CD40L). Frequencies were determined by in vitro Intracellular Cytokine Staining (ICS).","populationDescription":"The analyses were performed on the According-to-Protocol (ATP) Cohort for immunogenicity, which included all evaluable subjects from Month 0 to 3. This included those subjects who met all eligibility criteria, complied with the protocol, with no elimination criteria during this part of the study and for whom immunogenicity measures were available.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"VZV-specific CD4+ T-cells/million T-cell","timeFrame":"At Month 0 and at Month 2","groups":[{"id":"OG000","title":"Placebo Group","description":"Male or female subjects, 50 years of age or above, who received 2 doses of saline solution (placebo), administered intramuscularly in the upper deltoid region of the non-dominant arm, on a 0, 2 month schedule."},{"id":"OG001","title":"GSK1437173A Formulation 3 Group","description":"Male or female subjects, 50 years of age or above, who received 2 doses of GSK1437173A (gE/AS01B and gE/AS01E) formulation 3 vaccine, administered intramuscularly in the upper deltoid region of the non-dominant arm, on a 0, 2 month schedule."},{"id":"OG002","title":"GSK1437173A Formulation 2 Group","description":"Male or female subjects, 50 years of age or above, who received 2 doses of GSK1437173A (gE/AS01B and gE/AS01E) formulation 2 vaccine, administered intramuscularly in the upper deltoid region of the non-dominant arm, on a 0, 2 month schedule."},{"id":"OG003","title":"GSK1437173A Formulation 1 Group","description":"Male or female subjects, 50 years of age or above, who received 2 doses of GSK1437173A (gE/AS01B and gE/AS01E) formulation 1 vaccine, administered intramuscularly in the upper deltoid region of the non-dominant arm, on a 0, 2 month schedule."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"35"},{"groupId":"OG001","value":"68"},{"groupId":"OG002","value":"131"},{"groupId":"OG003","value":"133"}]}],"classes":[{"title":"Month 0","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"35"},{"groupId":"OG001","value":"65"},{"groupId":"OG002","value":"131"},{"groupId":"OG003","value":"133"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"533.97","spread":"422.46"},{"groupId":"OG001","value":"352.71","spread":"283.42"},{"groupId":"OG002","value":"457.28","spread":"402.04"},{"groupId":"OG003","value":"482.63","spread":"512.05"}]}]},{"title":"Month 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"33"},{"groupId":"OG001","value":"68"},{"groupId":"OG002","value":"124"},{"groupId":"OG003","value":"127"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"491.12","spread":"330.34"},{"groupId":"OG001","value":"410.69","spread":"356.65"},{"groupId":"OG002","value":"595.10","spread":"588.51"},{"groupId":"OG003","value":"574.54","spread":"586.85"}]}]}]},{"type":"SECONDARY","title":"Anti-gE Antibody Concentrations","description":"Concentrations were determined by enzyme-linked immunosorbent assay (ELISA) and are presented as geometric mean concentrations (GMCs), expressed in milli-international units per milliliter (mIU/mL).","populationDescription":"The analyses were performed on the According-to-Protocol (ATP) Cohort for immunogenicity, which included all evaluable subjects from Month 0 to 3. This included those subjects who met all eligibility criteria, complied with the protocol, with no elimination criteria during this part of the study and for whom immunogenicity measures were available.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"mIU/mL","timeFrame":"At Month 0 and at Month 2","groups":[{"id":"OG000","title":"Placebo Group","description":"Male or female subjects, 50 years of age or above, who received 2 doses of saline solution (placebo), administered intramuscularly in the upper deltoid region of the non-dominant arm, on a 0, 2 month schedule."},{"id":"OG001","title":"GSK1437173A Formulation 3 Group","description":"Male or female subjects, 50 years of age or above, who received 2 doses of GSK1437173A (gE/AS01B and gE/AS01E) formulation 3 vaccine, administered intramuscularly in the upper deltoid region of the non-dominant arm, on a 0, 2 month schedule."},{"id":"OG002","title":"GSK1437173A Formulation 2 Group","description":"Male or female subjects, 50 years of age or above, who received 2 doses of GSK1437173A (gE/AS01B and gE/AS01E) formulation 2 vaccine, administered intramuscularly in the upper deltoid region of the non-dominant arm, on a 0, 2 month schedule."},{"id":"OG003","title":"GSK1437173A Formulation 1 Group","description":"Male or female subjects, 50 years of age or above, who received 2 doses of GSK1437173A (gE/AS01B and gE/AS01E) formulation 1 vaccine, administered intramuscularly in the upper deltoid region of the non-dominant arm, on a 0, 2 month schedule."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"37"},{"groupId":"OG001","value":"71"},{"groupId":"OG002","value":"137"},{"groupId":"OG003","value":"140"}]}],"classes":[{"title":"Month 0","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"37"},{"groupId":"OG001","value":"71"},{"groupId":"OG002","value":"137"},{"groupId":"OG003","value":"140"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1907.7","lowerLimit":"1374.9","upperLimit":"2646.9"},{"groupId":"OG001","value":"1640.3","lowerLimit":"1307.9","upperLimit":"2057.3"},{"groupId":"OG002","value":"1526.7","lowerLimit":"1306.6","upperLimit":"1783.8"},{"groupId":"OG003","value":"1398.3","lowerLimit":"1212.6","upperLimit":"1612.5"}]}]},{"title":"Month 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"37"},{"groupId":"OG001","value":"70"},{"groupId":"OG002","value":"134"},{"groupId":"OG003","value":"133"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2022.3","lowerLimit":"1484.6","upperLimit":"2754.7"},{"groupId":"OG001","value":"10022.8","lowerLimit":"7593.7","upperLimit":"13228.7"},{"groupId":"OG002","value":"19962.3","lowerLimit":"16894.4","upperLimit":"23587.3"},{"groupId":"OG003","value":"23942.4","lowerLimit":"20536.9","upperLimit":"27912.6"}]}]}]},{"type":"SECONDARY","title":"Anti-VZV Antibody Concentrations","description":"Concentrations were determined by enzyme-linked immunosorbent assay (ELISA) and are presented as geometric mean concentrations (GMCs), expressed in milli-international units per milliliter (mIU/mL).","populationDescription":"The analyses were performed on the According-to-Protocol (ATP) Cohort for immunogenicity, which included all evaluable subjects from Month 0 to 3. This included those subjects who met all eligibility criteria, complied with the protocol, with no elimination criteria during this part of the study and for whom immunogenicity measures were available.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"mIU/mL","timeFrame":"At Month 0 and at Month 2","groups":[{"id":"OG000","title":"Placebo Group","description":"Male or female subjects, 50 years of age or above, who received 2 doses of saline solution (placebo), administered intramuscularly in the upper deltoid region of the non-dominant arm, on a 0, 2 month schedule."},{"id":"OG001","title":"GSK1437173A Formulation 3 Group","description":"Male or female subjects, 50 years of age or above, who received 2 doses of GSK1437173A (gE/AS01B and gE/AS01E) formulation 3 vaccine, administered intramuscularly in the upper deltoid region of the non-dominant arm, on a 0, 2 month schedule."},{"id":"OG002","title":"GSK1437173A Formulation 2 Group","description":"Male or female subjects, 50 years of age or above, who received 2 doses of GSK1437173A (gE/AS01B and gE/AS01E) formulation 2 vaccine, administered intramuscularly in the upper deltoid region of the non-dominant arm, on a 0, 2 month schedule."},{"id":"OG003","title":"GSK1437173A Formulation 1 Group","description":"Male or female subjects, 50 years of age or above, who received 2 doses of GSK1437173A (gE/AS01B and gE/AS01E) formulation 1 vaccine, administered intramuscularly in the upper deltoid region of the non-dominant arm, on a 0, 2 month schedule."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"37"},{"groupId":"OG001","value":"71"},{"groupId":"OG002","value":"137"},{"groupId":"OG003","value":"140"}]}],"classes":[{"title":"Month 0","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"37"},{"groupId":"OG001","value":"71"},{"groupId":"OG002","value":"137"},{"groupId":"OG003","value":"140"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1505.5","lowerLimit":"1191.7","upperLimit":"1901.9"},{"groupId":"OG001","value":"1289.6","lowerLimit":"1100.3","upperLimit":"1511.6"},{"groupId":"OG002","value":"1215.9","lowerLimit":"1077.4","upperLimit":"1372.2"},{"groupId":"OG003","value":"1175.8","lowerLimit":"1051.0","upperLimit":"1315.5"}]}]},{"title":"Month 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"37"},{"groupId":"OG001","value":"70"},{"groupId":"OG002","value":"134"},{"groupId":"OG003","value":"133"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1365.5","lowerLimit":"1074.4","upperLimit":"1735.4"},{"groupId":"OG001","value":"2392.8","lowerLimit":"2074.8","upperLimit":"2759.5"},{"groupId":"OG002","value":"3125.6","lowerLimit":"2902.8","upperLimit":"3365.5"},{"groupId":"OG003","value":"3355.1","lowerLimit":"3110.6","upperLimit":"3618.9"}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Any and Grade 3 Solicited Local Symptoms","description":"Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = pain that prevented normal activity. Grade 3 redness/swelling = redness/swelling spreading beyond 100 millimeters (mm) of injection site.","populationDescription":"The analyses were performed on the Total Vaccinated Cohort, which included all subjects with at least one vaccine administration documented, who had their symptom sheets filled in.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"During the 7-day (Days 0-6) post-vaccination period after each dose and across doses","groups":[{"id":"OG000","title":"Placebo Group","description":"Male or female subjects, 50 years of age or above, who received 2 doses of saline solution (placebo), administered intramuscularly in the upper deltoid region of the non-dominant arm, on a 0, 2 month schedule."},{"id":"OG001","title":"GSK1437173A Formulation 3 Group","description":"Male or female subjects, 50 years of age or above, who received 2 doses of GSK1437173A (gE/AS01B and gE/AS01E) formulation 3 vaccine, administered intramuscularly in the upper deltoid region of the non-dominant arm, on a 0, 2 month schedule."},{"id":"OG002","title":"GSK1437173A Formulation 2 Group","description":"Male or female subjects, 50 years of age or above, who received 2 doses of GSK1437173A (gE/AS01B and gE/AS01E) formulation 2 vaccine, administered intramuscularly in the upper deltoid region of the non-dominant arm, on a 0, 2 month schedule."},{"id":"OG003","title":"GSK1437173A Formulation 1 Group","description":"Male or female subjects, 50 years of age or above, who received 2 doses of GSK1437173A (gE/AS01B and gE/AS01E) formulation 1 vaccine, administered intramuscularly in the upper deltoid region of the non-dominant arm, on a 0, 2 month schedule."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"73"},{"groupId":"OG002","value":"149"},{"groupId":"OG003","value":"150"}]}],"classes":[{"title":"Any Pain, Dose 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"73"},{"groupId":"OG002","value":"149"},{"groupId":"OG003","value":"150"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"89"},{"groupId":"OG003","value":"112"}]}]},{"title":"Grade 3 Pain, Dose 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"73"},{"groupId":"OG002","value":"149"},{"groupId":"OG003","value":"150"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"}]}]},{"title":"Any Redness, Dose 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"73"},{"groupId":"OG002","value":"149"},{"groupId":"OG003","value":"150"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"15"},{"groupId":"OG003","value":"26"}]}]},{"title":"Grade 3 Redness, Dose 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"73"},{"groupId":"OG002","value":"149"},{"groupId":"OG003","value":"150"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"2"}]}]},{"title":"Any Swelling, Dose 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"73"},{"groupId":"OG002","value":"149"},{"groupId":"OG003","value":"150"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"9"},{"groupId":"OG003","value":"8"}]}]},{"title":"Grade 3 Swelling, Dose 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"73"},{"groupId":"OG002","value":"149"},{"groupId":"OG003","value":"150"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"}]}]},{"title":"Any Pain, Dose 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"37"},{"groupId":"OG001","value":"72"},{"groupId":"OG002","value":"143"},{"groupId":"OG003","value":"143"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"82"},{"groupId":"OG003","value":"106"}]}]},{"title":"Grade 3 Pain, Dose 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"37"},{"groupId":"OG001","value":"72"},{"groupId":"OG002","value":"143"},{"groupId":"OG003","value":"143"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"6"}]}]},{"title":"Any Redness, Dose 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"37"},{"groupId":"OG001","value":"72"},{"groupId":"OG002","value":"143"},{"groupId":"OG003","value":"143"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"19"},{"groupId":"OG003","value":"37"}]}]},{"title":"Grade 3 Redness, Dose 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"37"},{"groupId":"OG001","value":"72"},{"groupId":"OG002","value":"143"},{"groupId":"OG003","value":"143"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"1"}]}]},{"title":"Any Swelling, Dose 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"37"},{"groupId":"OG001","value":"72"},{"groupId":"OG002","value":"143"},{"groupId":"OG003","value":"143"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"20"},{"groupId":"OG003","value":"18"}]}]},{"title":"Grade 3 Swelling, Dose 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"37"},{"groupId":"OG001","value":"72"},{"groupId":"OG002","value":"143"},{"groupId":"OG003","value":"143"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"}]}]},{"title":"Any Pain, Across Doses","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"73"},{"groupId":"OG002","value":"149"},{"groupId":"OG003","value":"150"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"14"},{"groupId":"OG002","value":"104"},{"groupId":"OG003","value":"125"}]}]},{"title":"Grade 3 Pain, Across Doses","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"73"},{"groupId":"OG002","value":"149"},{"groupId":"OG003","value":"150"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"6"}]}]},{"title":"Any Redness, Across Doses","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"73"},{"groupId":"OG002","value":"149"},{"groupId":"OG003","value":"150"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"26"},{"groupId":"OG003","value":"44"}]}]},{"title":"Grade 3 Redness, Across Doses","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"73"},{"groupId":"OG002","value":"149"},{"groupId":"OG003","value":"150"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"2"}]}]},{"title":"Any Swelling, Across Doses","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"73"},{"groupId":"OG002","value":"149"},{"groupId":"OG003","value":"150"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"25"},{"groupId":"OG003","value":"23"}]}]},{"title":"Grade 3 Swelling, Across Doses","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"73"},{"groupId":"OG002","value":"149"},{"groupId":"OG003","value":"150"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"1"}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms.","description":"Assessed solicited general symptoms were fatigue, gastrointestinal symptoms, headache, myalgia and fever \\[defined as axillary temperature equal to or above (≥) 37.5 degrees Celsius (°C)\\]. Any = occurrence of the symptom regardless of intensity grade. Grade 3 symptom = symptom that prevented normal activity. Grade 3 fever = fever higher than (\\>) 39.0 °C. Related = symptom assessed by the investigator as related to the vaccination.","populationDescription":"The analyses were performed on the Total Vaccinated Cohort, which included all subjects with at least one vaccine administration documented, who had their symptom sheets filled in.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"During the 7-day (Days 0-6)post-vaccination period after each dose and across doses","groups":[{"id":"OG000","title":"Placebo Group","description":"Male or female subjects, 50 years of age or above, who received 2 doses of saline solution (placebo), administered intramuscularly in the upper deltoid region of the non-dominant arm, on a 0, 2 month schedule."},{"id":"OG001","title":"GSK1437173A Formulation 3 Group","description":"Male or female subjects, 50 years of age or above, who received 2 doses of GSK1437173A (gE/AS01B and gE/AS01E) formulation 3 vaccine, administered intramuscularly in the upper deltoid region of the non-dominant arm, on a 0, 2 month schedule."},{"id":"OG002","title":"GSK1437173A Formulation 2 Group","description":"Male or female subjects, 50 years of age or above, who received 2 doses of GSK1437173A (gE/AS01B and gE/AS01E) formulation 2 vaccine, administered intramuscularly in the upper deltoid region of the non-dominant arm, on a 0, 2 month schedule."},{"id":"OG003","title":"GSK1437173A Formulation 1 Group","description":"Male or female subjects, 50 years of age or above, who received 2 doses of GSK1437173A (gE/AS01B and gE/AS01E) formulation 1 vaccine, administered intramuscularly in the upper deltoid region of the non-dominant arm, on a 0, 2 month schedule."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"73"},{"groupId":"OG002","value":"149"},{"groupId":"OG003","value":"150"}]}],"classes":[{"title":"Any Fatigue, Dose 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"73"},{"groupId":"OG002","value":"149"},{"groupId":"OG003","value":"150"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"32"},{"groupId":"OG003","value":"42"}]}]},{"title":"Grade 3 Fatigue, Dose 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"73"},{"groupId":"OG002","value":"149"},{"groupId":"OG003","value":"150"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"2"}]}]},{"title":"Related Fatigue, Dose 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"73"},{"groupId":"OG002","value":"149"},{"groupId":"OG003","value":"150"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"28"},{"groupId":"OG003","value":"39"}]}]},{"title":"Any Gastr. sympt., Dose 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"73"},{"groupId":"OG002","value":"149"},{"groupId":"OG003","value":"150"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"8"}]}]},{"title":"Grade 3 Gastr. sympt., Dose 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"73"},{"groupId":"OG002","value":"149"},{"groupId":"OG003","value":"150"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"0"}]}]},{"title":"Related Gastr. sympt., Dose 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"73"},{"groupId":"OG002","value":"149"},{"groupId":"OG003","value":"150"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"7"},{"groupId":"OG003","value":"7"}]}]},{"title":"Any Headache, Dose 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"73"},{"groupId":"OG002","value":"149"},{"groupId":"OG003","value":"150"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"22"},{"groupId":"OG003","value":"32"}]}]},{"title":"Grade 3 Headache, Dose 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"73"},{"groupId":"OG002","value":"149"},{"groupId":"OG003","value":"150"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"}]}]},{"title":"Related Headache, Dose 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"73"},{"groupId":"OG002","value":"149"},{"groupId":"OG003","value":"150"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"14"},{"groupId":"OG003","value":"29"}]}]},{"title":"Any Myalgia, Dose 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"73"},{"groupId":"OG002","value":"149"},{"groupId":"OG003","value":"150"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"36"},{"groupId":"OG003","value":"42"}]}]},{"title":"Grade 3 Myalgia, Dose 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"73"},{"groupId":"OG002","value":"149"},{"groupId":"OG003","value":"150"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"2"}]}]},{"title":"Related Myalgia, Dose 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"73"},{"groupId":"OG002","value":"149"},{"groupId":"OG003","value":"150"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"29"},{"groupId":"OG003","value":"40"}]}]},{"title":"Any Temperature, Dose 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"73"},{"groupId":"OG002","value":"149"},{"groupId":"OG003","value":"150"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"7"},{"groupId":"OG003","value":"11"}]}]},{"title":"Grade 3 Temperature, Dose 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"73"},{"groupId":"OG002","value":"149"},{"groupId":"OG003","value":"150"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}]},{"title":"Related Temperature, Dose 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"73"},{"groupId":"OG002","value":"149"},{"groupId":"OG003","value":"150"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"8"}]}]},{"title":"Any Fatigue, Dose 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"37"},{"groupId":"OG001","value":"72"},{"groupId":"OG002","value":"143"},{"groupId":"OG003","value":"143"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"41"},{"groupId":"OG003","value":"58"}]}]},{"title":"Grade 3 Fatigue, Dose 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"37"},{"groupId":"OG001","value":"72"},{"groupId":"OG002","value":"143"},{"groupId":"OG003","value":"143"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"7"}]}]},{"title":"Related Fatigue, Dose 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"37"},{"groupId":"OG001","value":"72"},{"groupId":"OG002","value":"143"},{"groupId":"OG003","value":"143"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"34"},{"groupId":"OG003","value":"56"}]}]},{"title":"Any Gastr. sympt., Dose 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"37"},{"groupId":"OG001","value":"72"},{"groupId":"OG002","value":"143"},{"groupId":"OG003","value":"143"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"12"},{"groupId":"OG003","value":"12"}]}]},{"title":"Grade 3 Gastr. sympt., Dose 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"37"},{"groupId":"OG001","value":"72"},{"groupId":"OG002","value":"143"},{"groupId":"OG003","value":"143"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}]},{"title":"Related Gastr. sympt., Dose 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"37"},{"groupId":"OG001","value":"72"},{"groupId":"OG002","value":"143"},{"groupId":"OG003","value":"143"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"8"},{"groupId":"OG003","value":"9"}]}]},{"title":"Any Headache, Dose 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"37"},{"groupId":"OG001","value":"72"},{"groupId":"OG002","value":"143"},{"groupId":"OG003","value":"143"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"25"},{"groupId":"OG003","value":"42"}]}]},{"title":"Grade 3 Headache, Dose 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"37"},{"groupId":"OG001","value":"72"},{"groupId":"OG002","value":"143"},{"groupId":"OG003","value":"143"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"4"}]}]},{"title":"Related Headache, Dose 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"37"},{"groupId":"OG001","value":"72"},{"groupId":"OG002","value":"143"},{"groupId":"OG003","value":"143"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"20"},{"groupId":"OG003","value":"38"}]}]},{"title":"Any Myalgia, Dose 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"37"},{"groupId":"OG001","value":"72"},{"groupId":"OG002","value":"143"},{"groupId":"OG003","value":"143"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"33"},{"groupId":"OG003","value":"49"}]}]},{"title":"Grade 3 Myalgia, Dose 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"37"},{"groupId":"OG001","value":"72"},{"groupId":"OG002","value":"143"},{"groupId":"OG003","value":"143"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"6"}]}]},{"title":"Related Myalgia, Dose 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"37"},{"groupId":"OG001","value":"72"},{"groupId":"OG002","value":"143"},{"groupId":"OG003","value":"143"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"26"},{"groupId":"OG003","value":"48"}]}]},{"title":"Any Temperature, Dose 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"37"},{"groupId":"OG001","value":"72"},{"groupId":"OG002","value":"143"},{"groupId":"OG003","value":"143"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"14"},{"groupId":"OG003","value":"21"}]}]},{"title":"Grade 3 Temperature, Dose 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"37"},{"groupId":"OG001","value":"72"},{"groupId":"OG002","value":"143"},{"groupId":"OG003","value":"143"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}]},{"title":"Related Temperature, Dose 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"37"},{"groupId":"OG001","value":"72"},{"groupId":"OG002","value":"143"},{"groupId":"OG003","value":"143"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"11"},{"groupId":"OG003","value":"20"}]}]},{"title":"Any Fatigue, Across Doses","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"73"},{"groupId":"OG002","value":"149"},{"groupId":"OG003","value":"150"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"16"},{"groupId":"OG002","value":"52"},{"groupId":"OG003","value":"72"}]}]},{"title":"Grade 3 Fatigue, Across Doses","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"73"},{"groupId":"OG002","value":"149"},{"groupId":"OG003","value":"150"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"5"},{"groupId":"OG003","value":"9"}]}]},{"title":"Related Fatigue, Across Doses","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"73"},{"groupId":"OG002","value":"149"},{"groupId":"OG003","value":"150"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"14"},{"groupId":"OG002","value":"45"},{"groupId":"OG003","value":"71"}]}]},{"title":"Any Gastr. sympt., Across Doses","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"73"},{"groupId":"OG002","value":"149"},{"groupId":"OG003","value":"150"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"18"},{"groupId":"OG003","value":"17"}]}]},{"title":"Grade 3 Gastr. sympt., Across Doses","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"73"},{"groupId":"OG002","value":"149"},{"groupId":"OG003","value":"150"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"0"}]}]},{"title":"Related Gastr. sympt., Across Doses","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"73"},{"groupId":"OG002","value":"149"},{"groupId":"OG003","value":"150"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"12"},{"groupId":"OG003","value":"15"}]}]},{"title":"Any Headache, Across Doses","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"73"},{"groupId":"OG002","value":"149"},{"groupId":"OG003","value":"150"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"37"},{"groupId":"OG003","value":"56"}]}]},{"title":"Grade 3 Headache, Across Doses","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"73"},{"groupId":"OG002","value":"149"},{"groupId":"OG003","value":"150"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"5"}]}]},{"title":"Related Headache, Across Doses","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"73"},{"groupId":"OG002","value":"149"},{"groupId":"OG003","value":"150"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"29"},{"groupId":"OG003","value":"53"}]}]},{"title":"Any Myalgia, Across Doses","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"73"},{"groupId":"OG002","value":"149"},{"groupId":"OG003","value":"150"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"49"},{"groupId":"OG003","value":"62"}]}]},{"title":"Grade 3 Myalgia, Across Doses","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"73"},{"groupId":"OG002","value":"149"},{"groupId":"OG003","value":"150"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"7"}]}]},{"title":"Related Myalgia, Across Doses","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"73"},{"groupId":"OG002","value":"149"},{"groupId":"OG003","value":"150"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"41"},{"groupId":"OG003","value":"62"}]}]},{"title":"Any Temperature, Across Doses","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"73"},{"groupId":"OG002","value":"149"},{"groupId":"OG003","value":"150"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"18"},{"groupId":"OG003","value":"25"}]}]},{"title":"Grade 3 Temperature, Across Doses","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"73"},{"groupId":"OG002","value":"149"},{"groupId":"OG003","value":"150"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}]},{"title":"Related Temperature, Across Doses","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"73"},{"groupId":"OG002","value":"149"},{"groupId":"OG003","value":"150"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"13"},{"groupId":"OG003","value":"23"}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs)","description":"An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 AE = an AE which prevented normal, everyday activities. Related = AE assessed by the investigator as related to the vaccination.","populationDescription":"The analyses were performed on the Total Vaccinated Cohort, which included all subjects with at least one vaccine administration documented.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Within the 30-day (Days 0-29) post-vaccination period","groups":[{"id":"OG000","title":"Placebo Group","description":"Male or female subjects, 50 years of age or above, who received 2 doses of saline solution (placebo), administered intramuscularly in the upper deltoid region of the non-dominant arm, on a 0, 2 month schedule."},{"id":"OG001","title":"GSK1437173A Formulation 3 Group","description":"Male or female subjects, 50 years of age or above, who received 2 doses of GSK1437173A (gE/AS01B and gE/AS01E) formulation 3 vaccine, administered intramuscularly in the upper deltoid region of the non-dominant arm, on a 0, 2 month schedule."},{"id":"OG002","title":"GSK1437173A Formulation 2 Group","description":"Male or female subjects, 50 years of age or above, who received 2 doses of GSK1437173A (gE/AS01B and gE/AS01E) formulation 2 vaccine, administered intramuscularly in the upper deltoid region of the non-dominant arm, on a 0, 2 month schedule."},{"id":"OG003","title":"GSK1437173A Formulation 1 Group","description":"Male or female subjects, 50 years of age or above, who received 2 doses of GSK1437173A (gE/AS01B and gE/AS01E) formulation 1 vaccine, administered intramuscularly in the upper deltoid region of the non-dominant arm, on a 0, 2 month schedule."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"73"},{"groupId":"OG002","value":"149"},{"groupId":"OG003","value":"150"}]}],"classes":[{"title":"Any AE(s)","categories":[{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"18"},{"groupId":"OG002","value":"37"},{"groupId":"OG003","value":"46"}]}]},{"title":"Grade 3 AE(s)","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"5"}]}]},{"title":"Related AE(s)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"15"},{"groupId":"OG003","value":"24"}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Serious Adverse Events (SAEs)","description":"Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.","populationDescription":"The analyses were performed on the Total Vaccinated Cohort, which included all subjects with at least one vaccine administration documented.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"From Month 0 up to Month 8","groups":[{"id":"OG000","title":"Placebo Group","description":"Male or female subjects, 50 years of age or above, who received 2 doses of saline solution (placebo), administered intramuscularly in the upper deltoid region of the non-dominant arm, on a 0, 2 month schedule."},{"id":"OG001","title":"GSK1437173A Formulation 3 Group","description":"Male or female subjects, 50 years of age or above, who received 2 doses of GSK1437173A (gE/AS01B and gE/AS01E) formulation 3 vaccine, administered intramuscularly in the upper deltoid region of the non-dominant arm, on a 0, 2 month schedule."},{"id":"OG002","title":"GSK1437173A Formulation 2 Group","description":"Male or female subjects, 50 years of age or above, who received 2 doses of GSK1437173A (gE/AS01B and gE/AS01E) formulation 2 vaccine, administered intramuscularly in the upper deltoid region of the non-dominant arm, on a 0, 2 month schedule."},{"id":"OG003","title":"GSK1437173A Formulation 1 Group","description":"Male or female subjects, 50 years of age or above, who received 2 doses of GSK1437173A (gE/AS01B and gE/AS01E) formulation 1 vaccine, administered intramuscularly in the upper deltoid region of the non-dominant arm, on a 0, 2 month schedule."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"73"},{"groupId":"OG002","value":"149"},{"groupId":"OG003","value":"150"}]}],"classes":[{"title":"Up to Month 3","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"4"}]}]},{"title":"After Month 3 up to Month 8","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"2"}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Serious Adverse Events (SAEs)","description":"Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.","populationDescription":"The analyses were performed on the Total Vaccinated Cohort for the Safety Follow-up (SFU) Month 14, which included all vaccinated subjects who were not withdrawn from the study during the period up to Month 3 nor from the SFU Month 8, and who signed the supplementary informed consent for participating to the End of study telephone contact.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"During the period after Month 8 up to the end of the study at Month 14","groups":[{"id":"OG000","title":"Placebo Group","description":"Male or female subjects, 50 years of age or above, who received 2 doses of saline solution (placebo), administered intramuscularly in the upper deltoid region of the non-dominant arm, on a 0, 2 month schedule."},{"id":"OG001","title":"GSK1437173A Formulation 3 Group","description":"Male or female subjects, 50 years of age or above, who received 2 doses of GSK1437173A (gE/AS01B and gE/AS01E) formulation 3 vaccine, administered intramuscularly in the upper deltoid region of the non-dominant arm, on a 0, 2 month schedule."},{"id":"OG002","title":"GSK1437173A Formulation 2 Group","description":"Male or female subjects, 50 years of age or above, who received 2 doses of GSK1437173A (gE/AS01B and gE/AS01E) formulation 2 vaccine, administered intramuscularly in the upper deltoid region of the non-dominant arm, on a 0, 2 month schedule."},{"id":"OG003","title":"GSK1437173A Formulation 1 Group","description":"Male or female subjects, 50 years of age or above, who received 2 doses of GSK1437173A (gE/AS01B and gE/AS01E) formulation 1 vaccine, administered intramuscularly in the upper deltoid region of the non-dominant arm, on a 0, 2 month schedule."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"34"},{"groupId":"OG001","value":"65"},{"groupId":"OG002","value":"130"},{"groupId":"OG003","value":"126"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"4"}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Any New Onset of Autoimmune Diseases (NOADs)","description":"Any new onset of autoimmune diseases were to be reported throughout the entire study period, whether or not they were considered to be possibly related to the treatment administration. These included neurological/demyelinating events, rheumatic and connective diseases, autoimmune endocrine diseases, inflammatory bowel diseases, autoimmune blood disorders, inflammatory skin disorders, other autoimmune/inflammatory events, autoimmune bullous skin diseases, vasculitis and liver autoimmune diseases.","populationDescription":"The analyses were performed on the Total Vaccinated Cohort, which included all subjects with at least one vaccine administration documented.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"From Month 0 until Month 8","groups":[{"id":"OG000","title":"Placebo Group","description":"Male or female subjects, 50 years of age or above, who received 2 doses of saline solution (placebo), administered intramuscularly in the upper deltoid region of the non-dominant arm, on a 0, 2 month schedule."},{"id":"OG001","title":"GSK1437173A Formulation 3 Group","description":"Male or female subjects, 50 years of age or above, who received 2 doses of GSK1437173A (gE/AS01B and gE/AS01E) formulation 3 vaccine, administered intramuscularly in the upper deltoid region of the non-dominant arm, on a 0, 2 month schedule."},{"id":"OG002","title":"GSK1437173A Formulation 2 Group","description":"Male or female subjects, 50 years of age or above, who received 2 doses of GSK1437173A (gE/AS01B and gE/AS01E) formulation 2 vaccine, administered intramuscularly in the upper deltoid region of the non-dominant arm, on a 0, 2 month schedule."},{"id":"OG003","title":"GSK1437173A Formulation 1 Group","description":"Male or female subjects, 50 years of age or above, who received 2 doses of GSK1437173A (gE/AS01B and gE/AS01E) formulation 1 vaccine, administered intramuscularly in the upper deltoid region of the non-dominant arm, on a 0, 2 month schedule."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"73"},{"groupId":"OG002","value":"149"},{"groupId":"OG003","value":"150"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Any New Onset of Autoimmune Diseases (NOADs)","description":"Any new onset of autoimmune diseases were to be reported throughout the entire study period, whether or not they were considered to be possibly related to the treatment administration. These included neurological/demyelinating events, rheumatic and connective diseases, autoimmune endocrine diseases, inflammatory bowel diseases, autoimmune blood disorders, inflammatory skin disorders, other autoimmune/inflammatory events, autoimmune bullous skin diseases, vasculitis and liver autoimmune diseases.","populationDescription":"The analyses were performed on the Total Vaccinated Cohort for the Safety Follow-up (SFU) Month 14, which included all vaccinated subjects who were not withdrawn from the study during the period up to Month 3 nor from the SFU Month 8, and who signed the supplementary informed consent for participating to the End of study telephone contact.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"During the period after Month 8 up to the end of the study at Month 14","groups":[{"id":"OG000","title":"Placebo Group","description":"Male or female subjects, 50 years of age or above, who received 2 doses of saline solution (placebo), administered intramuscularly in the upper deltoid region of the non-dominant arm, on a 0, 2 month schedule."},{"id":"OG001","title":"GSK1437173A Formulation 3 Group","description":"Male or female subjects, 50 years of age or above, who received 2 doses of GSK1437173A (gE/AS01B and gE/AS01E) formulation 3 vaccine, administered intramuscularly in the upper deltoid region of the non-dominant arm, on a 0, 2 month schedule."},{"id":"OG002","title":"GSK1437173A Formulation 2 Group","description":"Male or female subjects, 50 years of age or above, who received 2 doses of GSK1437173A (gE/AS01B and gE/AS01E) formulation 2 vaccine, administered intramuscularly in the upper deltoid region of the non-dominant arm, on a 0, 2 month schedule."},{"id":"OG003","title":"GSK1437173A Formulation 1 Group","description":"Male or female subjects, 50 years of age or above, who received 2 doses of GSK1437173A (gE/AS01B and gE/AS01E) formulation 1 vaccine, administered intramuscularly in the upper deltoid region of the non-dominant arm, on a 0, 2 month schedule."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"34"},{"groupId":"OG001","value":"65"},{"groupId":"OG002","value":"130"},{"groupId":"OG003","value":"126"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Suspected Cases of Herpes Zoster (HZ)","description":"A suspected case of HZ was defined as a rash consistent with HZ.","populationDescription":"The analyses were performed on the Total Vaccinated Cohort, which included all subjects with at least one vaccine administration documented.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"From Month 0 until Month 8","groups":[{"id":"OG000","title":"Placebo Group","description":"Male or female subjects, 50 years of age or above, who received 2 doses of saline solution (placebo), administered intramuscularly in the upper deltoid region of the non-dominant arm, on a 0, 2 month schedule."},{"id":"OG001","title":"GSK1437173A Formulation 3 Group","description":"Male or female subjects, 50 years of age or above, who received 2 doses of GSK1437173A (gE/AS01B and gE/AS01E) formulation 3 vaccine, administered intramuscularly in the upper deltoid region of the non-dominant arm, on a 0, 2 month schedule."},{"id":"OG002","title":"GSK1437173A Formulation 2 Group","description":"Male or female subjects, 50 years of age or above, who received 2 doses of GSK1437173A (gE/AS01B and gE/AS01E) formulation 2 vaccine, administered intramuscularly in the upper deltoid region of the non-dominant arm, on a 0, 2 month schedule."},{"id":"OG003","title":"GSK1437173A Formulation 1 Group","description":"Male or female subjects, 50 years of age or above, who received 2 doses of GSK1437173A (gE/AS01B and gE/AS01E) formulation 1 vaccine, administered intramuscularly in the upper deltoid region of the non-dominant arm, on a 0, 2 month schedule."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"73"},{"groupId":"OG002","value":"149"},{"groupId":"OG003","value":"150"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Suspected Cases of Herpes Zoster (HZ)","description":"A suspected case of HZ is defined as a rash consistent with HZ.","populationDescription":"The analyses were performed on the Total Vaccinated Cohort for the Safety Follow-up (SFU) Month 14, which included all vaccinated subjects who were not withdrawn from the study during the period up to Month 3 nor from the SFU Month 8, and who signed the supplementary informed consent for participating to the End of study telephone contact.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"During the period after Month 8 up to the end of the study at Month 14","groups":[{"id":"OG000","title":"Placebo Group","description":"Male or female subjects, 50 years of age or above, who received 2 doses of saline solution (placebo), administered intramuscularly in the upper deltoid region of the non-dominant arm, on a 0, 2 month schedule."},{"id":"OG001","title":"GSK1437173A Formulation 3 Group","description":"Male or female subjects, 50 years of age or above, who received 2 doses of GSK1437173A (gE/AS01B and gE/AS01E) formulation 3 vaccine, administered intramuscularly in the upper deltoid region of the non-dominant arm, on a 0, 2 month schedule."},{"id":"OG002","title":"GSK1437173A Formulation 2 Group","description":"Male or female subjects, 50 years of age or above, who received 2 doses of GSK1437173A (gE/AS01B and gE/AS01E) formulation 2 vaccine, administered intramuscularly in the upper deltoid region of the non-dominant arm, on a 0, 2 month schedule."},{"id":"OG003","title":"GSK1437173A Formulation 1 Group","description":"Male or female subjects, 50 years of age or above, who received 2 doses of GSK1437173A (gE/AS01B and gE/AS01E) formulation 1 vaccine, administered intramuscularly in the upper deltoid region of the non-dominant arm, on a 0, 2 month schedule."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"34"},{"groupId":"OG001","value":"65"},{"groupId":"OG002","value":"130"},{"groupId":"OG003","value":"126"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Haematological and Biochemical Parameters Unknown, Below, Within or Above the Normal Ranges","description":"Hematological and biochemical parameters assessed were Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Basophils (BAS), Calcium (CAL), Creatinine (CREA), Eosinophils (EOS), Fibrinogen (FIBR), Hematocrit (HCT), Hemoglobin (HGB), Lactate Dehydrogenase (LDH), Lymphocytes (LYM), Mean Corpuscular Volume (MCV), Monocytes (MON), Neutrophils (NEU), Partial Thromboplastin Time (PTT), Platelets (PLAT), Prothrombin Time (PT), Red Blood Cells (RBC), Total Protein (TP) and White Blood Cells (WBC).","populationDescription":"The analyses were performed on the Total Vaccinated Cohort, which included all subjects with at least one vaccine administration documented.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"At Month 0","groups":[{"id":"OG000","title":"Placebo Group","description":"Male or female subjects, 50 years of age or above, who received 2 doses of saline solution (placebo), administered intramuscularly in the upper deltoid region of the non-dominant arm, on a 0, 2 month schedule."},{"id":"OG001","title":"GSK1437173A Formulation 1 Group","description":"Male or female subjects, 50 years of age or above, who received 2 doses of GSK1437173A (gE/AS01B and gE/AS01E) formulation 1 vaccine, administered intramuscularly in the upper deltoid region of the non-dominant arm, on a 0, 2 month schedule."},{"id":"OG002","title":"GSK1437173A Formulation 2 Group","description":"Male or female subjects, 50 years of age or above, who received 2 doses of GSK1437173A (gE/AS01B and gE/AS01E) formulation 2 vaccine, administered intramuscularly in the upper deltoid region of the non-dominant arm, on a 0, 2 month schedule."},{"id":"OG003","title":"GSK1437173A Formulation 3 Group","description":"Male or female subjects, 50 years of age or above, who received 2 doses of GSK1437173A (gE/AS01B and gE/AS01E) formulation 3 vaccine, administered intramuscularly in the upper deltoid region of the non-dominant arm, on a 0, 2 month schedule."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"150"},{"groupId":"OG002","value":"149"},{"groupId":"OG003","value":"73"}]}],"classes":[{"title":"ALT","categories":[{"title":"Unknown","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]},{"title":"Below","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]},{"title":"Normal","measurements":[{"groupId":"OG000","value":"35"},{"groupId":"OG001","value":"146"},{"groupId":"OG002","value":"142"},{"groupId":"OG003","value":"71"}]},{"title":"Above","measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"7"},{"groupId":"OG003","value":"2"}]}]},{"title":"AST","categories":[{"title":"Unknown","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]},{"title":"Below","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]},{"title":"Normal","measurements":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"148"},{"groupId":"OG002","value":"146"},{"groupId":"OG003","value":"71"}]},{"title":"Above","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"2"}]}]},{"title":"BAS","categories":[{"title":"Unknown","measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"}]},{"title":"Below","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]},{"title":"Normal","measurements":[{"groupId":"OG000","value":"37"},{"groupId":"OG001","value":"148"},{"groupId":"OG002","value":"148"},{"groupId":"OG003","value":"73"}]},{"title":"Above","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}]},{"title":"CAL","categories":[{"title":"Unknown","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]},{"title":"Below","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]},{"title":"Normal","measurements":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"150"},{"groupId":"OG002","value":"144"},{"groupId":"OG003","value":"73"}]},{"title":"Above","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"5"},{"groupId":"OG003","value":"0"}]}]},{"title":"CREA","categories":[{"title":"Unknown","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]},{"title":"Below","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]},{"title":"Normal","measurements":[{"groupId":"OG000","value":"36"},{"groupId":"OG001","value":"144"},{"groupId":"OG002","value":"142"},{"groupId":"OG003","value":"70"}]},{"title":"Above","measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"7"},{"groupId":"OG003","value":"3"}]}]},{"title":"EOS","categories":[{"title":"Unknown","measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"}]},{"title":"Below","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"12"},{"groupId":"OG003","value":"8"}]},{"title":"Normal","measurements":[{"groupId":"OG000","value":"36"},{"groupId":"OG001","value":"132"},{"groupId":"OG002","value":"135"},{"groupId":"OG003","value":"65"}]},{"title":"Above","measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"}]}]},{"title":"FIBR","categories":[{"title":"Unknown","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"1"}]},{"title":"Below","measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"0"}]},{"title":"Normal","measurements":[{"groupId":"OG000","value":"34"},{"groupId":"OG001","value":"127"},{"groupId":"OG002","value":"126"},{"groupId":"OG003","value":"56"}]},{"title":"Above","measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"18"},{"groupId":"OG002","value":"18"},{"groupId":"OG003","value":"16"}]}]},{"title":"HCT","categories":[{"title":"Unknown","measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"}]},{"title":"Below","measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"9"},{"groupId":"OG003","value":"1"}]},{"title":"Normal","measurements":[{"groupId":"OG000","value":"35"},{"groupId":"OG001","value":"135"},{"groupId":"OG002","value":"135"},{"groupId":"OG003","value":"71"}]},{"title":"Above","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"1"}]}]},{"title":"HGB","categories":[{"title":"Unknown","measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"}]},{"title":"Below","measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"7"},{"groupId":"OG003","value":"1"}]},{"title":"Normal","measurements":[{"groupId":"OG000","value":"36"},{"groupId":"OG001","value":"141"},{"groupId":"OG002","value":"137"},{"groupId":"OG003","value":"70"}]},{"title":"Above","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"2"}]}]},{"title":"LDH","categories":[{"title":"Unknown","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]},{"title":"Below","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]},{"title":"Normal","measurements":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"149"},{"groupId":"OG002","value":"149"},{"groupId":"OG003","value":"73"}]},{"title":"Above","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}]},{"title":"LYM","categories":[{"title":"Unknown","measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"}]},{"title":"Below","measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"1"}]},{"title":"Normal","measurements":[{"groupId":"OG000","value":"35"},{"groupId":"OG001","value":"146"},{"groupId":"OG002","value":"145"},{"groupId":"OG003","value":"72"}]},{"title":"Above","measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"0"}]}]},{"title":"MCV","categories":[{"title":"Unknown","measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"}]},{"title":"Below","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"2"}]},{"title":"Normal","measurements":[{"groupId":"OG000","value":"37"},{"groupId":"OG001","value":"140"},{"groupId":"OG002","value":"145"},{"groupId":"OG003","value":"69"}]},{"title":"Above","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"2"}]}]},{"title":"MON","categories":[{"title":"Unknown","measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"}]},{"title":"Below","measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"2"}]},{"title":"Normal","measurements":[{"groupId":"OG000","value":"36"},{"groupId":"OG001","value":"142"},{"groupId":"OG002","value":"144"},{"groupId":"OG003","value":"71"}]},{"title":"Above","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}]},{"title":"NEU","categories":[{"title":"Unknown","measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"}]},{"title":"Below","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]},{"title":"Normal","measurements":[{"groupId":"OG000","value":"37"},{"groupId":"OG001","value":"142"},{"groupId":"OG002","value":"146"},{"groupId":"OG003","value":"71"}]},{"title":"Above","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"2"}]}]},{"title":"PTT","categories":[{"title":"Unknown","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"1"}]},{"title":"Below","measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"5"},{"groupId":"OG003","value":"1"}]},{"title":"Normal","measurements":[{"groupId":"OG000","value":"36"},{"groupId":"OG001","value":"135"},{"groupId":"OG002","value":"137"},{"groupId":"OG003","value":"70"}]},{"title":"Above","measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"5"},{"groupId":"OG003","value":"1"}]}]},{"title":"PLAT","categories":[{"title":"Unknown","measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"0"}]},{"title":"Below","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"1"}]},{"title":"Normal","measurements":[{"groupId":"OG000","value":"35"},{"groupId":"OG001","value":"144"},{"groupId":"OG002","value":"143"},{"groupId":"OG003","value":"70"}]},{"title":"Above","measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"2"}]}]},{"title":"PT","categories":[{"title":"Unknown","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"1"}]},{"title":"Below","measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"3"}]},{"title":"Normal","measurements":[{"groupId":"OG000","value":"35"},{"groupId":"OG001","value":"135"},{"groupId":"OG002","value":"137"},{"groupId":"OG003","value":"67"}]},{"title":"Above","measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"8"},{"groupId":"OG003","value":"2"}]}]},{"title":"RBC","categories":[{"title":"Unknown","measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"}]},{"title":"Below","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"2"}]},{"title":"Normal","measurements":[{"groupId":"OG000","value":"37"},{"groupId":"OG001","value":"141"},{"groupId":"OG002","value":"142"},{"groupId":"OG003","value":"68"}]},{"title":"Above","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"3"}]}]},{"title":"TP","categories":[{"title":"Unknown","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]},{"title":"Below","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]},{"title":"Normal","measurements":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"149"},{"groupId":"OG002","value":"148"},{"groupId":"OG003","value":"73"}]},{"title":"Above","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"}]}]},{"title":"WBC","categories":[{"title":"Unknown","measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"}]},{"title":"Below","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"}]},{"title":"Normal","measurements":[{"groupId":"OG000","value":"37"},{"groupId":"OG001","value":"145"},{"groupId":"OG002","value":"140"},{"groupId":"OG003","value":"70"}]},{"title":"Above","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"8"},{"groupId":"OG003","value":"2"}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Haematological and Biochemical Parameters Unknown, Below, Within or Above the Normal Ranges","description":"Hematological and biochemical parameters assessed were Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Basophils (BAS), Calcium (CAL), Creatinine (CREA), Eosinophils (EOS), Fibrinogen (FIBR), Hematocrit (HCT), Hemoglobin (HGB), Lactate Dehydrogenase (LDH), Lymphocytes (LYM), Mean Corpuscular Volume (MCV), Monocytes (MON), Neutrophils (NEU), Partial Thromboplastin Time (PTT), Platelets (PLAT), Prothrombin Time (PT), Red Blood Cells (RBC), Total Protein (TP) and White Blood Cells (WBC).","populationDescription":"The analyses were performed on the Month 2 Total Vaccinated Cohort, which included all subjects with at least one vaccine administration documented and who completed the Month 2 study visit.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"At Month 2","groups":[{"id":"OG000","title":"Placebo Group","description":"Male or female subjects, 50 years of age or above, who received 2 doses of saline solution (placebo), administered intramuscularly in the upper deltoid region of the non-dominant arm, on a 0, 2 month schedule."},{"id":"OG001","title":"GSK1437173A Formulation 1 Group","description":"Male or female subjects, 50 years of age or above, who received 2 doses of GSK1437173A (gE/AS01B and gE/AS01E) formulation 1 vaccine, administered intramuscularly in the upper deltoid region of the non-dominant arm, on a 0, 2 month schedule."},{"id":"OG002","title":"GSK1437173A Formulation 2 Group","description":"Male or female subjects, 50 years of age or above, who received 2 doses of GSK1437173A (gE/AS01B and gE/AS01E) formulation 2 vaccine, administered intramuscularly in the upper deltoid region of the non-dominant arm, on a 0, 2 month schedule."},{"id":"OG003","title":"GSK1437173A Formulation 3 Group","description":"Male or female subjects, 50 years of age or above, who received 2 doses of GSK1437173A (gE/AS01B and gE/AS01E) formulation 3 vaccine, administered intramuscularly in the upper deltoid region of the non-dominant arm, on a 0, 2 month schedule."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"143"},{"groupId":"OG002","value":"144"},{"groupId":"OG003","value":"72"}]}],"classes":[{"title":"ALT","categories":[{"title":"Unknown","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]},{"title":"Below","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]},{"title":"Normal","measurements":[{"groupId":"OG000","value":"36"},{"groupId":"OG001","value":"139"},{"groupId":"OG002","value":"138"},{"groupId":"OG003","value":"68"}]},{"title":"Above","measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"4"}]}]},{"title":"AST","categories":[{"title":"Unknown","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"}]},{"title":"Below","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]},{"title":"Normal","measurements":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"139"},{"groupId":"OG002","value":"140"},{"groupId":"OG003","value":"67"}]},{"title":"Above","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"4"}]}]},{"title":"BAS","categories":[{"title":"Unknown","measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"2"}]},{"title":"Below","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]},{"title":"Normal","measurements":[{"groupId":"OG000","value":"37"},{"groupId":"OG001","value":"140"},{"groupId":"OG002","value":"142"},{"groupId":"OG003","value":"70"}]},{"title":"Above","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}]},{"title":"CAL","categories":[{"title":"Unknown","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"}]},{"title":"Below","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"}]},{"title":"Normal","measurements":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"137"},{"groupId":"OG002","value":"136"},{"groupId":"OG003","value":"71"}]},{"title":"Above","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"7"},{"groupId":"OG003","value":"0"}]}]},{"title":"CREA","categories":[{"title":"Unknown","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"}]},{"title":"Below","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]},{"title":"Normal","measurements":[{"groupId":"OG000","value":"37"},{"groupId":"OG001","value":"138"},{"groupId":"OG002","value":"138"},{"groupId":"OG003","value":"67"}]},{"title":"Above","measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"4"}]}]},{"title":"EOS","categories":[{"title":"Unknown","measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"2"}]},{"title":"Below","measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"12"},{"groupId":"OG003","value":"7"}]},{"title":"Normal","measurements":[{"groupId":"OG000","value":"35"},{"groupId":"OG001","value":"125"},{"groupId":"OG002","value":"129"},{"groupId":"OG003","value":"62"}]},{"title":"Above","measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"1"}]}]},{"title":"FIBR","categories":[{"title":"Unknown","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"0"}]},{"title":"Below","measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"9"}]},{"title":"Normal","measurements":[{"groupId":"OG000","value":"34"},{"groupId":"OG001","value":"124"},{"groupId":"OG002","value":"131"},{"groupId":"OG003","value":"59"}]},{"title":"Above","measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"4"}]}]},{"title":"HCT","categories":[{"title":"Unknown","measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"1"}]},{"title":"Below","measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"11"},{"groupId":"OG003","value":"4"}]},{"title":"Normal","measurements":[{"groupId":"OG000","value":"35"},{"groupId":"OG001","value":"126"},{"groupId":"OG002","value":"126"},{"groupId":"OG003","value":"65"}]},{"title":"Above","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"5"},{"groupId":"OG003","value":"2"}]}]},{"title":"HGB","categories":[{"title":"Unknown","measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"1"}]},{"title":"Below","measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"7"},{"groupId":"OG003","value":"3"}]},{"title":"Normal","measurements":[{"groupId":"OG000","value":"35"},{"groupId":"OG001","value":"129"},{"groupId":"OG002","value":"134"},{"groupId":"OG003","value":"66"}]},{"title":"Above","measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"2"}]}]},{"title":"LDH","categories":[{"title":"Unknown","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]},{"title":"Below","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]},{"title":"Normal","measurements":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"143"},{"groupId":"OG002","value":"144"},{"groupId":"OG003","value":"71"}]},{"title":"Above","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"}]}]},{"title":"LYM","categories":[{"title":"Unknown","measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"2"}]},{"title":"Below","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"3"}]},{"title":"Normal","measurements":[{"groupId":"OG000","value":"37"},{"groupId":"OG001","value":"137"},{"groupId":"OG002","value":"139"},{"groupId":"OG003","value":"67"}]},{"title":"Above","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"}]}]},{"title":"MCV","categories":[{"title":"Unknown","measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"1"}]},{"title":"Below","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"3"}]},{"title":"Normal","measurements":[{"groupId":"OG000","value":"37"},{"groupId":"OG001","value":"134"},{"groupId":"OG002","value":"139"},{"groupId":"OG003","value":"67"}]},{"title":"Above","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"1"}]}]},{"title":"MON","categories":[{"title":"Unknown","measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"2"}]},{"title":"Below","measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"9"},{"groupId":"OG003","value":"6"}]},{"title":"Normal","measurements":[{"groupId":"OG000","value":"34"},{"groupId":"OG001","value":"130"},{"groupId":"OG002","value":"133"},{"groupId":"OG003","value":"64"}]},{"title":"Above","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}]},{"title":"NEU","categories":[{"title":"Unknown","measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"2"}]},{"title":"Below","measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"1"}]},{"title":"Normal","measurements":[{"groupId":"OG000","value":"36"},{"groupId":"OG001","value":"136"},{"groupId":"OG002","value":"138"},{"groupId":"OG003","value":"68"}]},{"title":"Above","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"1"}]}]},{"title":"PTT","categories":[{"title":"Unknown","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"0"}]},{"title":"Below","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"}]},{"title":"Normal","measurements":[{"groupId":"OG000","value":"37"},{"groupId":"OG001","value":"132"},{"groupId":"OG002","value":"129"},{"groupId":"OG003","value":"64"}]},{"title":"Above","measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"11"},{"groupId":"OG003","value":"8"}]}]},{"title":"PLAT","categories":[{"title":"Unknown","measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"2"}]},{"title":"Below","measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"5"},{"groupId":"OG003","value":"0"}]},{"title":"Normal","measurements":[{"groupId":"OG000","value":"36"},{"groupId":"OG001","value":"137"},{"groupId":"OG002","value":"135"},{"groupId":"OG003","value":"68"}]},{"title":"Above","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"2"}]}]},{"title":"PT","categories":[{"title":"Unknown","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"0"}]},{"title":"Below","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"}]},{"title":"Normal","measurements":[{"groupId":"OG000","value":"37"},{"groupId":"OG001","value":"136"},{"groupId":"OG002","value":"132"},{"groupId":"OG003","value":"67"}]},{"title":"Above","measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"8"},{"groupId":"OG003","value":"5"}]}]},{"title":"RBC","categories":[{"title":"Unknown","measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"1"}]},{"title":"Below","measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"3"}]},{"title":"Normal","measurements":[{"groupId":"OG000","value":"36"},{"groupId":"OG001","value":"131"},{"groupId":"OG002","value":"131"},{"groupId":"OG003","value":"66"}]},{"title":"Above","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"2"}]}]},{"title":"TP","categories":[{"title":"Unknown","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]},{"title":"Below","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]},{"title":"Normal","measurements":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"142"},{"groupId":"OG002","value":"144"},{"groupId":"OG003","value":"72"}]},{"title":"Above","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}]},{"title":"WBC","categories":[{"title":"Unknown","measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"2"}]},{"title":"Below","measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"}]},{"title":"Normal","measurements":[{"groupId":"OG000","value":"35"},{"groupId":"OG001","value":"133"},{"groupId":"OG002","value":"139"},{"groupId":"OG003","value":"67"}]},{"title":"Above","measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"2"}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Haematological and Biochemical Parameters Unknown, Below, Within or Above the Normal Ranges","description":"Hematological and biochemical parameters assessed were Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Basophils (BAS), Calcium (CAL), Creatinine (CREA), Eosinophils (EOS), Fibrinogen (FIBR), Hematocrit (HCT), Hemoglobin (HGB), Lactate Dehydrogenase (LDH), Lymphocytes (LYM), Mean Corpuscular Volume (MCV), Monocytes (MON), Neutrophils (NEU), Partial Thromboplastin Time (PTT), Platelets (PLAT), Prothrombin Time (PT), Red Blood Cells (RBC), Total Protein (TP) and White Blood Cells (WBC).","populationDescription":"The analyses were performed on the Month 3 Total Vaccinated Cohort, which included all subjects with at least one vaccine administration documented and who completed the Month 3 study visit.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"At Month 3","groups":[{"id":"OG000","title":"Placebo Group","description":"Male or female subjects, 50 years of age or above, who received 2 doses of saline solution (placebo), administered intramuscularly in the upper deltoid region of the non-dominant arm, on a 0, 2 month schedule."},{"id":"OG001","title":"GSK1437173A Formulation 1 Group","description":"Male or female subjects, 50 years of age or above, who received 2 doses of GSK1437173A (gE/AS01B and gE/AS01E) formulation 1 vaccine, administered intramuscularly in the upper deltoid region of the non-dominant arm, on a 0, 2 month schedule."},{"id":"OG002","title":"GSK1437173A Formulation 2 Group","description":"Male or female subjects, 50 years of age or above, who received 2 doses of GSK1437173A (gE/AS01B and gE/AS01E) formulation 2 vaccine, administered intramuscularly in the upper deltoid region of the non-dominant arm, on a 0, 2 month schedule."},{"id":"OG003","title":"GSK1437173A Formulation 3 Group","description":"Male or female subjects, 50 years of age or above, who received 2 doses of GSK1437173A (gE/AS01B and gE/AS01E) formulation 3 vaccine, administered intramuscularly in the upper deltoid region of the non-dominant arm, on a 0, 2 month schedule."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"142"},{"groupId":"OG002","value":"142"},{"groupId":"OG003","value":"72"}]}],"classes":[{"title":"ALT","categories":[{"title":"Unknown","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]},{"title":"Below","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]},{"title":"Normal","measurements":[{"groupId":"OG000","value":"36"},{"groupId":"OG001","value":"138"},{"groupId":"OG002","value":"139"},{"groupId":"OG003","value":"70"}]},{"title":"Above","measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"2"}]}]},{"title":"AST","categories":[{"title":"Unknown","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]},{"title":"Below","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]},{"title":"Normal","measurements":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"139"},{"groupId":"OG002","value":"140"},{"groupId":"OG003","value":"70"}]},{"title":"Above","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"2"}]}]},{"title":"BAS","categories":[{"title":"Unknown","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"3"}]},{"title":"Below","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]},{"title":"Normal","measurements":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"139"},{"groupId":"OG002","value":"139"},{"groupId":"OG003","value":"69"}]},{"title":"Above","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}]},{"title":"CAL","categories":[{"title":"Unknown","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]},{"title":"Below","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"}]},{"title":"Normal","measurements":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"140"},{"groupId":"OG002","value":"138"},{"groupId":"OG003","value":"71"}]},{"title":"Above","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"0"}]}]},{"title":"CREA","categories":[{"title":"Unknown","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]},{"title":"Below","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]},{"title":"Normal","measurements":[{"groupId":"OG000","value":"37"},{"groupId":"OG001","value":"135"},{"groupId":"OG002","value":"134"},{"groupId":"OG003","value":"68"}]},{"title":"Above","measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"8"},{"groupId":"OG003","value":"4"}]}]},{"title":"EOS","categories":[{"title":"Unknown","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"3"}]},{"title":"Below","measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"13"},{"groupId":"OG003","value":"11"}]},{"title":"Normal","measurements":[{"groupId":"OG000","value":"36"},{"groupId":"OG001","value":"131"},{"groupId":"OG002","value":"122"},{"groupId":"OG003","value":"57"}]},{"title":"Above","measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"1"}]}]},{"title":"FIBR","categories":[{"title":"Unknown","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"2"}]},{"title":"Below","measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"2"}]},{"title":"Normal","measurements":[{"groupId":"OG000","value":"35"},{"groupId":"OG001","value":"125"},{"groupId":"OG002","value":"133"},{"groupId":"OG003","value":"61"}]},{"title":"Above","measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"5"},{"groupId":"OG003","value":"7"}]}]},{"title":"HCT","categories":[{"title":"Unknown","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"4"}]},{"title":"Below","measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"6"}]},{"title":"Normal","measurements":[{"groupId":"OG000","value":"34"},{"groupId":"OG001","value":"126"},{"groupId":"OG002","value":"126"},{"groupId":"OG003","value":"61"}]},{"title":"Above","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"1"}]}]},{"title":"HGB","categories":[{"title":"Unknown","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"3"}]},{"title":"Below","measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"5"},{"groupId":"OG003","value":"3"}]},{"title":"Normal","measurements":[{"groupId":"OG000","value":"35"},{"groupId":"OG001","value":"127"},{"groupId":"OG002","value":"133"},{"groupId":"OG003","value":"65"}]},{"title":"Above","measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"1"}]}]},{"title":"LDH","categories":[{"title":"Unknown","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]},{"title":"Below","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]},{"title":"Normal","measurements":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"141"},{"groupId":"OG002","value":"142"},{"groupId":"OG003","value":"71"}]},{"title":"Above","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"}]}]},{"title":"LYM","categories":[{"title":"Unknown","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"3"}]},{"title":"Below","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"1"}]},{"title":"Normal","measurements":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"136"},{"groupId":"OG002","value":"136"},{"groupId":"OG003","value":"68"}]},{"title":"Above","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"}]}]},{"title":"MCV","categories":[{"title":"Unknown","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"4"}]},{"title":"Below","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"4"}]},{"title":"Normal","measurements":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"133"},{"groupId":"OG002","value":"137"},{"groupId":"OG003","value":"63"}]},{"title":"Above","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"1"}]}]},{"title":"MON","categories":[{"title":"Unknown","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"3"}]},{"title":"Below","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"13"},{"groupId":"OG003","value":"8"}]},{"title":"Normal","measurements":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"130"},{"groupId":"OG002","value":"126"},{"groupId":"OG003","value":"61"}]},{"title":"Above","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}]},{"title":"NEU","categories":[{"title":"Unknown","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"3"}]},{"title":"Below","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]},{"title":"Normal","measurements":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"135"},{"groupId":"OG002","value":"138"},{"groupId":"OG003","value":"65"}]},{"title":"Above","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"4"}]}]},{"title":"PTT","categories":[{"title":"Unknown","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"2"}]},{"title":"Below","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]},{"title":"Normal","measurements":[{"groupId":"OG000","value":"37"},{"groupId":"OG001","value":"131"},{"groupId":"OG002","value":"136"},{"groupId":"OG003","value":"68"}]},{"title":"Above","measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"2"}]}]},{"title":"PLAT","categories":[{"title":"Unknown","measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"4"}]},{"title":"Below","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"1"}]},{"title":"Normal","measurements":[{"groupId":"OG000","value":"37"},{"groupId":"OG001","value":"131"},{"groupId":"OG002","value":"134"},{"groupId":"OG003","value":"66"}]},{"title":"Above","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"1"}]}]},{"title":"PT","categories":[{"title":"Unknown","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"2"}]},{"title":"Below","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]},{"title":"Normal","measurements":[{"groupId":"OG000","value":"37"},{"groupId":"OG001","value":"131"},{"groupId":"OG002","value":"137"},{"groupId":"OG003","value":"68"}]},{"title":"Above","measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"5"},{"groupId":"OG003","value":"2"}]}]},{"title":"RBC","categories":[{"title":"Unknown","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"4"}]},{"title":"Below","measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"8"},{"groupId":"OG003","value":"2"}]},{"title":"Normal","measurements":[{"groupId":"OG000","value":"36"},{"groupId":"OG001","value":"131"},{"groupId":"OG002","value":"131"},{"groupId":"OG003","value":"64"}]},{"title":"Above","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"2"}]}]},{"title":"TP","categories":[{"title":"Unknown","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]},{"title":"Below","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]},{"title":"Normal","measurements":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"142"},{"groupId":"OG002","value":"142"},{"groupId":"OG003","value":"72"}]},{"title":"Above","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}]},{"title":"WBC","categories":[{"title":"Unknown","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"3"}]},{"title":"Below","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"2"}]},{"title":"Normal","measurements":[{"groupId":"OG000","value":"37"},{"groupId":"OG001","value":"132"},{"groupId":"OG002","value":"137"},{"groupId":"OG003","value":"64"}]},{"title":"Above","measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"3"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"Solicited local/general symptoms: during the 7-day post-vaccination period (Days 0-6); Unsolicited AEs: during the 30-day post-vaccination period (Days 0-29); SAEs: during the entire study period (Day 0 - Month 14).","eventGroups":[{"id":"EG000","title":"Placebo Group","description":"Male or female subjects, 50 years of age or above, who received 2 doses of saline solution (placebo), administered intramuscularly in the upper deltoid region of the non-dominant arm, on a 0, 2 month schedule.","deathsNumAffected":0,"deathsNumAtRisk":38,"seriousNumAffected":3,"seriousNumAtRisk":38,"otherNumAffected":9,"otherNumAtRisk":38},{"id":"EG001","title":"GSK1437173A Formulation 3 Group","description":"Male or female subjects, 50 years of age or above, who received 2 doses of GSK1437173A (gE/AS01B and gE/AS01E) formulation 3 vaccine, administered intramuscularly in the upper deltoid region of the non-dominant arm, on a 0, 2 month schedule.","deathsNumAffected":2,"deathsNumAtRisk":73,"seriousNumAffected":8,"seriousNumAtRisk":73,"otherNumAffected":31,"otherNumAtRisk":73},{"id":"EG002","title":"GSK1437173A Formulation 2 Group","description":"Male or female subjects, 50 years of age or above, who received 2 doses of GSK1437173A (gE/AS01B and gE/AS01E) formulation 2 vaccine, administered intramuscularly in the upper deltoid region of the non-dominant arm, on a 0, 2 month schedule.","deathsNumAffected":0,"deathsNumAtRisk":149,"seriousNumAffected":6,"seriousNumAtRisk":149,"otherNumAffected":114,"otherNumAtRisk":149},{"id":"EG003","title":"GSK1437173A Formulation 1 Group","description":"Male or female subjects, 50 years of age or above, who received 2 doses of GSK1437173A (gE/AS01B and gE/AS01E) formulation 1 vaccine, administered intramuscularly in the upper deltoid region of the non-dominant arm, on a 0, 2 month schedule.","deathsNumAffected":1,"deathsNumAtRisk":150,"seriousNumAffected":10,"seriousNumAtRisk":150,"otherNumAffected":131,"otherNumAtRisk":150}],"seriousEvents":[{"term":"Acute myocardial infarction","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":73},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":149},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":150}]},{"term":"Atrial fibrillation","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":73},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":149},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":150}]},{"term":"Bradycardia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":73},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":149},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":150}]},{"term":"Cardiac failure","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":73},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":149},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":150}]},{"term":"Coronary artery occlusion","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":73},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":149},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":150}]},{"term":"Myocardial infarction","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":73},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":149},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":150}]},{"term":"Myocardial ischaemia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":73},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":149},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":150}]},{"term":"Sinus node dysfunction","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":73},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":149},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":150}]},{"term":"Hiatus hernia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":38},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":73},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":149},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":150}]},{"term":"Ileus","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":73},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":149},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":150}]},{"term":"Pancreatic mass","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":73},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":149},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":150}]},{"term":"Subileus","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":73},{"groupId":"EG002","numEvents":2,"numAffected":1,"numAtRisk":149},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":150}]},{"term":"Upper gastrointestinal haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":73},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":149},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":150}]},{"term":"Chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":73},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":149},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":150}]},{"term":"Hernia","organSystem":"General disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":73},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":149},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":150}]},{"term":"Bile duct obstruction","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":73},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":149},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":150}]},{"term":"Cholelithiasis","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":38},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":73},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":149},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":150}]},{"term":"Appendicitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":73},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":149},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":150}]},{"term":"Diverticulitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":73},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":149},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":150}]},{"term":"Escherichia sepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":73},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":149},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":150}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":73},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":149},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":150}]},{"term":"Femur fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":73},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":149},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":150}]},{"term":"Osteoarthritis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":38},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":73},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":149},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":150}]},{"term":"Bladder cancer","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":73},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":149},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":150}]},{"term":"Plasma cell myeloma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":73},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":149},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":150}]},{"term":"Cerebrovascular disorder","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":73},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":149},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":150}]},{"term":"Syncope","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":73},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":149},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":150}]},{"term":"Transient ischaemic attack","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":73},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":149},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":150}]},{"term":"Depression","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":73},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":149},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":150}]},{"term":"Acute kidney injury","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":73},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":149},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":150}]},{"term":"Renal failure","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":73},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":149},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":150}]},{"term":"Pulmonary embolism","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":73},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":149},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":150}]},{"term":"Respiratory failure","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":73},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":149},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":150}]},{"term":"Haematoma","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":73},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":149},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":150}]}],"otherEvents":[{"term":"Chills","organSystem":"General disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":73},{"groupId":"EG002","numEvents":4,"numAffected":3,"numAtRisk":149},{"groupId":"EG003","numEvents":10,"numAffected":8,"numAtRisk":150}]},{"term":"Erythema","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":73},{"groupId":"EG002","numEvents":36,"numAffected":27,"numAtRisk":149},{"groupId":"EG003","numEvents":66,"numAffected":47,"numAtRisk":150}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":7,"numAtRisk":38},{"groupId":"EG001","numEvents":20,"numAffected":16,"numAtRisk":73},{"groupId":"EG002","numEvents":73,"numAffected":52,"numAtRisk":149},{"groupId":"EG003","numEvents":101,"numAffected":73,"numAtRisk":150}]},{"term":"Gastrointestinal disorder","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":38},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":73},{"groupId":"EG002","numEvents":22,"numAffected":18,"numAtRisk":149},{"groupId":"EG003","numEvents":20,"numAffected":17,"numAtRisk":150}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":5,"numAtRisk":38},{"groupId":"EG001","numEvents":14,"numAffected":11,"numAtRisk":73},{"groupId":"EG002","numEvents":50,"numAffected":37,"numAtRisk":149},{"groupId":"EG003","numEvents":76,"numAffected":57,"numAtRisk":150}]},{"term":"Myalgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":2,"numAtRisk":38},{"groupId":"EG001","numEvents":16,"numAffected":12,"numAtRisk":73},{"groupId":"EG002","numEvents":69,"numAffected":49,"numAtRisk":149},{"groupId":"EG003","numEvents":93,"numAffected":63,"numAtRisk":150}]},{"term":"Pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":38},{"groupId":"EG001","numEvents":17,"numAffected":14,"numAtRisk":73},{"groupId":"EG002","numEvents":171,"numAffected":104,"numAtRisk":149},{"groupId":"EG003","numEvents":220,"numAffected":126,"numAtRisk":150}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":38},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":73},{"groupId":"EG002","numEvents":21,"numAffected":18,"numAtRisk":149},{"groupId":"EG003","numEvents":33,"numAffected":26,"numAtRisk":150}]},{"term":"Swelling","organSystem":"General disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":73},{"groupId":"EG002","numEvents":29,"numAffected":25,"numAtRisk":149},{"groupId":"EG003","numEvents":27,"numAffected":24,"numAtRisk":150}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial."},"pointOfContact":{"title":"GSK Response Center","organization":"GlaxoSmithKline","phone":"866-435-7343"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-11-09"},"conditionBrowseModule":{"meshes":[{"id":"D006562","term":"Herpes Zoster"},{"id":"D002644","term":"Chickenpox"}],"ancestors":[{"id":"D000073618","term":"Varicella Zoster Virus Infection"},{"id":"D006566","term":"Herpesviridae Infections"},{"id":"D004266","term":"DNA Virus Infections"},{"id":"D014777","term":"Virus Diseases"},{"id":"D007239","term":"Infections"}]},"interventionBrowseModule":{"meshes":[{"id":"D012965","term":"Sodium Chloride"}],"ancestors":[{"id":"D002712","term":"Chlorides"},{"id":"D006851","term":"Hydrochloric Acid"},{"id":"D017606","term":"Chlorine Compounds"},{"id":"D007287","term":"Inorganic Chemicals"},{"id":"D017670","term":"Sodium Compounds"}]}},"hasResults":true}